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Differential Activity of the KRAS Oncogene by Method of Activation: Implications for Signaling
and Therapeutic Intervention
By Nathan Ihle B.S.
Despite having been identified over thirty years ago and definitively established as having a
critical role in driving tumor growth and predicting for resistance to therapy, the KRAS
oncogene remains a target in cancer for which there is no effective treatment. KRas is
activated by mutations at a few sites, primarily amino acid substitutions at codon 12 which
promote a constitutively active state. I have found that different amino acid substitutions at
codon 12 can activate different KRas downstream signaling pathways, determine clonogenic
growth potential and determine patient response to molecularly targeted therapies. Computer
modeling of the KRas structure shows that different amino acids substituted at the codon 12
position influences how KRas interacts with its effecters.
In the absence of a direct inhibitor of mutant KRas several agents have recently entered
clinical trials alone and in combination directly targeting two of the common downstream
effecter pathways of KRas, namely the Mapk pathway and the Akt pathway. These inhibitors
were evaluated for efficacy against different KRAS activating mutations. An isogenic panel of
colorectal cells with wild type KRas replaced with KRas G12C, G12D, or G12V at the
endogenous loci differed in sensitivity to Mek and Akt inhibition. In contrast, screening was
performed in a broad panel of lung cell lines alone and no correlation was seen between types
of activating KRAS mutation due to concurrent oncogenic lesions.
To find a new method to inhibit KRAS driven tumors, siRNA screens were performed in
isogenic lines with and without active KRas. The knockdown of CNKSR1 (CNK1) showed
selective growth inhibition in cells with an oncogenic KRAS. The deletion of CNK1 reduces
expression of mitotic cell cycle proteins and arrests cells with active KRas in the G1 phase of
the cell cycle similar to the deletion of an activated KRas regardless of activating substitution.
v

CNK1 has a PH domain responsible for localizing it to membrane lipids making KRas
potentially amenable to inhibition with small molecules. The work has identified a series of
small molecules capable of binding to this PH domain and inhibiting CNK1 facilitated KRas
signaling.
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Introduction
1.1

Ras background and function
The Ras superfamily of enzymes consists of over 100 GTP hydrolysis switch proteins

(small GTPases) responsible for signal propagation and includes the Ras, Rho, Arf, Ran, and
Rab proteins1. The name Ras is derived from Rat Sarcoma, the model system in which this
class of enzymes was first described in 19622. Twenty years later the human homologues
were identified by Scolnick and colleagues as genes important in human cancer 3. These small
GTPases are similar in structure to the Gα subunit of the heterotrimeric G proteins (large
GTPases) but lack the presence of the Gβ and Gγ subunits as additional regulators 4. The Ras
enzymes exist in dynamic equilibrium, either bound to GDP and considered inactive or bound
to GTP in which state they are capable of engaging multiple effecter proteins. Ras enzymes
directly bind effecters changing their conformation creating an active state in which
downstream signaling is engaged. This signaling can have immediate effects on cellular
processes such as metabolism and survival and can influence DNA transcription leading to
global cellular outcomes such as altered motility, growth and differentiation. The four identified
human Ras proteins (K-Ras4A, K-Ras4B, N-Ras, and H-Ras) within the Ras superfamily
share approximately 85% sequence homology. These subtypes differ mainly at a C-terminus
in a string of residues termed the “hypervariable region” responsible for the appropriate
localization of these enzymes 5. The two KRas proteins arise from the same gene and are a
product of alternative gene splicing and differ in this hypervariable region. Activation of these
proteins comes from the gamma phosphate of GTP interacting at the two switch regions
(usually at residues threonine 35 of switch 1 and glycine 60 of switch 2) within the Ras
proteins pulling them together into what is termed the “loaded spring” confirmation 6. In this
“loaded spring” confirmation the switch regions are contorted in such a fashion that effecter
binding becomes favorable. The Ras proteins are capable of acting on their own nucleotide,
and thus can self-hydrolyze their own GTP molecule to GDP resulting in de-activation, but
1

require additional regulator proteins that amplify this process for appropriate physiological
control of activity.
1.1.1

The Ras activation Cycle
The Ras proteins are activated in response to the engagement of growth factor

receptors. Upon a growth factor binding to the extracellular domain of the receptor, an
intracellular region of the receptor undergoes a conformational change and is phosphorylated
on tyrosine residues 7. These phosphorylations promote binding of proteins containing SH2
domains to the tyrosine sites. SH2 domain-containing proteins, known as adaptor proteins,
bind to an activated receptor can activate Guanine Exchange factors (GEFs). GEF’s interact
with the Ras proteins and elicit the release of the currently bound nucleotide8 The result of this
is the exchange of the previously utilized GDP nucleotide for a new GTP, as GTP occurs at a
ten-fold higher concentration in the cytosol. The Ras enzyme becomes active and transduces
intracellular signals through other GTPases and kinases, thus linking the presence of
extracellular growth factors to intracellular signaling cascades. The most extensively
characterized GEF is SOS1, first identified as an essential regulator of Drosophila
melanogaster eye development9 and later characterized in human cells as essential for
neurodevelopmental pathway acting as a intracellular messenger for the epithelial growth
factor receptor (EGFR) 10. Later Grb2 was found to facilitate the activation of Sos1 by growth
factor receptors either by direct binding 11 or through binding to other adaptor proteins which
are directly bound to these receptors such as FRS for FGFR signaling12 and IRS to elicit
insulin receptor induced Sos1 activation and the Ras signaling cascade 13. Additionally the
RasGEF Cdc25 was found through studies in the yeast S. cerevisiae as a link between the
adenylate cyclase pathway and Ras activation 14 and later the mammalian homolog was
established 15. In murine embryonic cells, the Cdc25 mediated activation of Ras signaling was
found to be an important regulator of early development 16.
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The Ras enzymes have an intrinsic rate of hydrolysis thus deactivating the enzyme; however
this rate is insufficient for appropriate biological control. In 1987, Trahey and McCormick
isolated an enzyme, which came to be known as p120 RasGAP, that binds the Ras enzymes
and accelerated the rate of hydrolysis of GTP by 300 fold 17,18. Later NF2 was also discovered
to act as a RasGAP during the search to characterize the tumor suppressor responsible for
Neurofibromatosis type II, an inheritable condition causing benign brain tumors that result in
loss of hearing 19. These RasGAPs increase the hydrolysis of GTP bound Ras by binding to
the catalytic site on this Ras and reorienting a water molecule using an arginine residue
dubbed the “arginine finger.” Upon RasGAP binding to Ras this water molecule becomes
oriented in a position favoring a nucleophilic attack on the GTP nucleotide 20 . This Ras cycle
of activation and inactivation is depicted in Figure 1.
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Figure 1

Figure 1: Mechanism of Ras activation. After a growth factor binds a growth factor receptor,
Grb2 binds to the receptor allowing the activation of the Sos RasGEF proteins. These Sos
proteins promote the dissociation of GDP allowing for the binding of GTP. The gamma
phosphate of GTP interacts with the switch I and II regions of Ras resulting in dramatic
structural changes allowing effecter binding and activation. Ras has intrinsic GTPase activity
and thus removes the gamma phosphate the bound GTP to yield GDP. This conversion is
aided by the binding of RasGAPs.
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1.1.2

Ras localization

In addition to the nucleotide exchange to GTP, localization of the protein to membranes is
necessary for activation of Ras. This localization is accomplished by recognition of posttranslational modifications in the C-terminus “hypervariable region” where anchoring moieties
are attached 5. Within this region, a CaaX box of Ras gets farnesylated at the Cys residue in
resulting in the insertion for Ras into cellular membranes. This is followed by the tripeptide
(aaX) being cleaved from the C-terminus by a prenyl-protein specific endoprotease. The
modified C-terminus is then methylated by a methyltransferase in a fashion unique to different
Ras isoforms. HRas undergos palmitoylation on two cysteine residues adjacent to the CaaX
box and NRas has a single cysteine site that undergoes palmitoylation. These palmintoylations
result in the anchoring of these proteins to the membrane. The KRas4A splice variant
undergoes a single palymitoylation step similar to NRas but KRas 4B differs in this
hypervariable region by having this site replaced by a stretch of positively charged lysines in
this region which associate with negatively charged membrane lipids 21. This result of these
modifications is the movement of HRas, NRas, and KRas4A from assembly in the
endoplasmic reticulum to the golgi appratus and then to caveloae, a cholesterol binding
protein in the membrane22. These Ras isoforms then undergo a dynamic cycle of
palmitoylation and de-palmitoylation allowing shuttling between the plasma membrane and the
golgi apparatus. In contrast, KRas is transported directly from the ER to the membrane by
unknown mechanisms and is found independent of caveloae in membranes 23. The
localization of the different Ras isoforms is represented in Figure 2.
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Figure 2

Figure 2: Localization of Ras isoforms to the membrane. The Ras isoforms are anchored
to membranes through the addition of a farnesyl group, NRas is additionally anchored to the
membrane through the addition of a single farnesyl while HRas and KRas4A have a second
farnesyl group. Alternatively KRas interacts with the membrane through a stretch of lysines
which create a positive charge attracting the enzyme to negatively charged membrane lipids.
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1.1.3 KRAS in development
Despite their high homology the function of the Ras proteins differs significantly in
normal physiological signaling. Both HRAS and NRAS have been found to be dispensable for
normal development in mice24,25 as has the KRAS4A splice variant of KRAS26. Additionally, the
concurrent deletion of HRAS and NRAS shows no discernible phenotype 27.In contrast,
KRAS4B knockout is embryonic lethal although the introduction of alternative RAS isoforms at
the KRAS locus will rescue this phenotype28. KRAS4B deficient embryos fail in gestation
between day 12 and day 14 post fertilization and this lethality is thought to be due to
hematopoietic defects caused by a dysfunctional microenvironment in the fetal liver. Despite
this, many tissues in the developing mouse undergo normal growth and differentiation despite
no compensatory increases in levels of HRas or NRas protein expression being observed 25.
Like KRAS deletion microinjection of a dominant negative Ras N-17, which abrogates all Ras
signaling was embryonic lethal and suggested that Ras activity is required for mouse embryos
to develop beyond the two cell stage presumed to be due to the necessity of this pathway for
autocrine factor growth stimulation 29.
In humans a series of inheritable and spontaneous genetic modifications give rise to
growth deformities known collectively as “RASopathies.” These are a collection on syndromes
all arising from mutations that result in the improper activation of the Ras pathway, and thus
may serve as a model for the role of Ras in normal development 30. The most common
RASopathy is the inheritable disorder Noonan syndrome, occuring in 1/1000 to 1/2500
individuals in the United States. This disorder can be caused by activating mutations in SOS1,
KRAS, or inactivating mutations in SHP2, a phosphatase that acts on growth factor regulated
pathways, including RAS. The sites of these activating mutations in KRAS are different than
those seem in human tumors 31. This deregulated Ras signaling leads to an extensive set of
developmental problems including facial dysmorphism, skeletal defects, blood defects, heart
problems, neurological disorders and dwarfism 32.
7

1.2 KRas signal transduction
There are seven confirmed downstream signaling proteins activated by KRas33 . The first
of these identified was RAF1, revealed through detailed screening in Drosophila melanogaster
where Ras and Raf were shown to phenocopy each other in the regulation of eye34 and
phenocopy vulval fate in C. elegans development35. This enzyme has been thoroughly
characterized as an activator of Mek- Erk signal transduction, important for growth and
development36. Mammals process three Raf isoforms, ARAF, BRAF, and RAF1. BRAF is the
isoform with the greatest similarity to Raf in Drosophila harboring acidic resides in sites
phosphorylated through growth factor stimulation in C-Raf (RAF1) and the ramifications of this
difference remains unclear 37. Ras is known to primarily utilize B-Raf to elicit the Mek-Erk
response, while C-Raf and A-Raf may have evolved to serve both alternative functions
including the inhibition of differentiation and promotion of endocytosis respectively 38,39. The
next Ras effecter elucidated was the p110 catalytic subunit of PI3K40. When discovered, PI3K
had already been characterized as an enzyme responsible for converting the membrane lipid
PIP2 to PIP3. PIP3 results in the recruitment of a specific subset of signaling kinases containing
a pleckstrin homology (PH) domain to the membrane for activation. The best characterized of
the PH domain containing proteins in this group is Akt which plays an important role in growth
and metabolism. Four isoforms of PI3K exist: alpha, beta, delta and gamma of which alpha
and gamma are confirmed Ras effecters 41. Mice created with a PI3Kα isoform which was
genetically modified to be deficient in Ras binding showed embryonic lethality due to deficient
lymphogenesis, displaying a phenotype similar to mice with vascular endothelial growth factor
receptor-3 (VEGFR3) deficency 42. These proteins allowed the elucidation of the common
structural features of Ras effecters, the Ras binding domain or the Ras association domain
(RA), and more effecters began to emerge as a result of massive screening efforts. The first of
these was RALGDS, an activator the RALA and RALB GTPases, which contains an RA
domain43. The Ral GTPases have been demonstrated to play an important role in endocytosis,
8

the exocyst complex, and nutrient sensing. Ras also binds PLCε 44, a phospholipase C
isoform with an RA domain responsible for Ras mediated production of the membrane lipid
DAG which results in calcium release and activation of the PKC signaling cascade45. Finally,
Ras binds Tiam1, an enzyme which is utilized in integrin signaling46 and plays an extensive
role in T cell trafficking through its control of the chemokine and S1P response making it
necessary for the mounting of an appropriate immune response47.
While these effecters are associated with growth and survival another set of Ras effecter
RA domain containing proteins associated with apoptosis have been identified; namely the
RASSF family of enzymes48. While the entire set of RASSF proteins have a RA domain, only a
subset is confirmed as Ras binders. While it is known that the Ras-RASSF complex engages
the pro-apoptotic complex Mst1 many details of this pathway remain to be discovered49. The
Ras effecters are shown in Figure 3.
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Figure 3

Figure 3: Ras effecter pathways. Validated effecters of Ras signaling and the pathways
activated by each. A majority of Ras effecter pathways promote cellular functions such as
growth, survival, and motility. Unique among these effecters is RASSF1 which is known to
induce apoptosis.
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1.3 KRAS in Cancer
The Ras proteins have been intertwined with the study of cancer biology cancer since
the initial discovery as the oncogenic Harvey sarcoma activating virus in 1964 and the Kirsten
murine sarcoma virus in 19672,50. In 1981, the insertion product from these viruses was
identified in DNA isolated from a human cancer cell line and by 1982 it was discovered that
mutations were present in RAS which promoted transformation 3. Over thirty years later, we
know an estimated 320,000 individuals diagnosed with cancer in the US will carry mutant
KRAS (mut-KRAS), yet there is still no effective therapy directed against activated KRas 51.
Of the RAS isoforms, KRAS4B is the most frequently activated through mutation in human
cancer. Mutations in KRAS are particularly prevalent in cancers that arise from the ectoderm,
such as colorectal cancer 52, lung cancer 53 and pancreatic cancer 54 for reasons not currently
delineated. KRAS4A is not activated in cancer and instead is thought to induce apoptosis upon
activation, even being hypothesized to be a tumor suppressor 55. HRAS and NRAS are both
known to be activated in specific disease types with HRAS commonly activated in bladder
cancer and NRAS being activated in melanoma. The reason for the disease specific
prevalence of activating mutations in these isoforms remains a matter of debate

56

.

1.3.1 Activating KRAS mutations
Amino acid substitution mutations occurring in codon 12 are the most frequent in
human tumors but substitutions in codons 13 and 61 also occur and result in KRas activation.
These mutations result in the enzyme being “locked” or spending increased time in the GTP
bound state due to an insensitivity to RasGAPs 17. Glycine, an amino acid lacking a side
chain, is the amino acid found at both the 12 and 13 codons in the wild type KRas protein.
The introduction of any side chain containing amino acid at the codon 12 or 13 positions with
the exception of proline serves to hyperactivate the KRas enzyme 57. These amino acids at
codon 12 inhibit the formation of Van der Waals bonds between RasGAP and Ras by
disrupting the proper orientation of the catalytic glutamine for the γ-phosphate of GTP found at
11

codon 6158. Alternatively, codon 61 substitutions that occur less frequently, activating KRas
through a similar mechanism indicating the essential nature of codon 61 in KRas deactivation.
Intriguingly, despite the observation that a majority of amino acids at codons 12,13 and 61 are
activating for KRas particular amino acid substitutions are associated with both cancer and
particular codon and amino acids are associated with particular types of cancer56.
1.3.2 KRAS as a driver of tumorigenesis
Early studies to establish KRAS as a driver of tumorigenesis were hindered by the
finding that overexpressed activated KRas in mouse embryonic fibroblasts resulted in growth
arrest unless cell cycle inhibitory checkpoint proteins are deleted 59. It was later discovered
that endogenous levels of active KRas in these cells leads to overexpression of key
components of the cell cycle and enhanced proliferation without the deletion of these
checkpoints 60. KRAS mutations are among the highest prevalence in solid tumor
malignancies as approximately 30% of cancer patients are likely to have KRAS mutated
tumors 61. KRAS has also been established in multiple systems to be integral in driving other
hallmarks of cancer development and progression, such as the evasion of apoptosis and
angiogenesis under hypoxic conditions62, cancer invasion into proximal tissues and the
establishment of cancer metastases at distant sites63. In human tumors activating KRAS
mutations occur frequently in lung adenocarcinomas, particularly non-small cell lung cancer
(NSCLC) where around 30% of patients have KRAS mutations 64 and in colorectal cancer
where approximately 35–40% of patients have KRAS mutations, which are classically
described as being associated with progression of a benign adenoma to a dysplastic
adenocarcinoma52. In pancreatic cancer, a majority of ductal endocarcinomas have KRAS
mutations 54. Much of the evidence that KRAS is driver of tumorigenesis has come from
mouse models where a mutant KRas (usually G12D) is specifically activated in a tissue after
full development of the mouse to induce tumorgenesis. To fully recapitulate advanced human
disease it is necessary to have alteration of a second gene with INK4A/ARF deficiency
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cooperating with KRAS in the induction of mouse pancreatic tumors 65 and the loss of APC
cooperating with KRAS in the induction of colon tumors 66. In contrast to these finding is the
observation that mutant KRAS is sufficient by itself to induce cancer in the lungs 67. However,
the combination of KRAS with other genetic alterations commonly found in lung tumors, such
as STK11 (LKB1) or p53 loss, increase the severity of the disease resulting in decreased
differentiation and increased metastasis 68, providing increased resistance to multiple
therapies 69.
1.3.3 KRAS in cancer therapy
In the last ten years the focus of cancer therapy has shifted from the inhibition of global
cellular processes, particularly chemotherapy that aims to inhibit cell division, to targeted
therapies to inhibit the specific deregulated enzymes found uniquely in tumors. Arguably the
first attempt at a “targeted therapy” was against active Ras. While some of these efforts
focused on the development of a small molecule mimetic to RasGAP70, the most promising
approach was thought to be the inhibition of Ras farnesylation which would block the post
translational modification responsible for the correct membrane localization of active Ras with
its effecters and thus inhibit its activity 71. Additional excitement behind this concept was driven
by the knowledge that the farnesyl pyrophosphate that attaches this group to proteins is an
obligate intermediate component of the mevalonate-cholesterol synthesis pathway already
targeted by the drug lovastatin, approved by the FDA in 1987. However, the clinically relevant
concentration was found to be much lower than the concentration needed to block Ras
farnesylation ruling out this agent as a viable option for cancer therapy72. The effort was
specifically targeted toward the development of agents inhibiting the enzyme responsible for
the addition of the farnesyl group to Ras, namely farnesyltransferase, and resulted in the
development of potent inhibitors to this enzyme 73. These inhibitors showed antitumor activity
in HRas driven models 74. However it was soon found that both KRas and NRas could
undergo an alternative prenylation via the geranylgeranyltransferase enzyme when
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farnesyltranferase was inhibited still allowing for correct membrane localization75. As activated
KRas and NRas are far more common in human cancers than HRas the FTIs subsequently
failed in clinical trials but are still being evaluated in bladder cancer which has a high
proportion of HRAS mutations56.
From this early role as a candidate target for directed therapy, today mutated KRAS
has emerged as a confirmed predictor of resistance to many targeted cancer therapies76.
While, the effects of mutated KRAS on chemotherapy are still debated. In targeted treatment
KRAS is widely accepted as a resistance mechanism for growth factor receptor directed
therapies such as EGFR inhibitors, where it serves as a clinical marker which excludes such
treatment for patients with colorectal cancer 77. Therapies to individual KRas effecters have
proven effective in diseases where KRas effecters are activated independently of KRas
including the clinical activity of selective BRaf inhibitors in melanomas with activating BRaf
mutations 78, and studies showing increased efficacy of PI3K inhibitors in PI3K mutant tumors
79

. In contrast, mutant NRAS or KRAS have shown to predict lack of response to both these

agents 80. This is hypothesized to result from redundant growth and survival signals relayed
simultaneously through Ras which activates multiple effecters simultaneously. This led to the
idea that concurrent inhibition of multiple KRas effecters may lead to patient response in
tumors with a mutant KRas 79 currently being tested in clinical trials.
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Materials and methods
2.1 BATTLE clinical trial
Data from the BATTLE clinical trial of patients with refractory NSCLC who agreed to a
baseline tumor biopsy procedure, receiving either erlotinib, vandetanib, bexarotene and
erlotinib, or sorafenib was analyzed for the effects of different mut-KRas amino acid
substitutions on patient progression free survival. Radiographic imaging of tumors was
reviewed to determine suitability for biopsy. Eligibility included age  18 years and adequate
performance status (ECOG grade 0 – 2). Prior treatment with erlotinib was allowed but these
patients were excluded from the erlotinib-containing study arms, and stable (for at least 4
weeks) or treated brain metastases were permitted. All participants provided written informed
consent.
2.2 Patient microarray data
Frozen tissue for mRNA profiling was obtained from 189 patients. Among 139 patients
with available gene expression profiles, 101 were randomized and evaluable for 8 week
disease control. The patient breakdown was 27 erlotinib, 8 erlotinib and bexarotene, 47
sorafenib, and 19 vandetanib. All steps leading to generation of gene expression profiles from
patient tumor core biopsies were conducted by the University of Texas M.D. Anderson Cancer
Center Genomics Core Facility using the human Gene 1.0 ST Array (Affymetrix). RNA was
extracted and purified from OCT-embedded tissue using the RNeasy Mini Kit (Qiagen)
including on-column DNase (Qiagen) digestion as described by the manufacturer's protocol.
An H&E stained section of all the samples was available to check for presence of stratified
epithelium. After RNA quantification using a ND-1000 spectrophotometer (Nanodrop
Technologies), all RNAs were serially diluted in RNAse-free water to obtain a 250 pg/μL stock
solution. RNA quality was measured by analyzing separation trace of RNA using the RNA6000
PicoAssay for the Bioanalyzer 2100 (Agilent). Aliquots were prepared and stored at -80°C. The
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same RNA was used for all experiments as starting RNA for amplification. Each aliquot was
used once.
RNA amplifications were performed using the WT-Ovation™ Pico RNA Amplification
System (NuGEN). For all experiments, the manufacturers' protocols were strictly followed. The
Ribo-SPIA™ technique is a three-step process that generates amplified cDNA from as little as
500 picograms of total RNA. First strand cDNA is prepared from total RNA using a unique first
strand DNA/RNA chimeric primer mix. The primers have a DNA portion that hybridizes either
to the 5' portion of the poly(A) sequence or randomly across the transcript. Reverse
transcriptase extends the 3' DNA end of each primer generating first strand cDNA/mRNA
hybrid. Second strand cDNA synthesis step generates double stranded products with RNADNA heteroduplex at one end. The third step is the DNA amplification using a specific
DNA/RNA chimeric primer, DNA polymerase and RNase H in a homogeneous isothermal
assay that provides highly efficient amplification of DNA sequences. RNase H is used to
degrade RNA in the DNA/RNA heteroduplex at the 5' end of the first cDNA strand. This results
in the exposure of a DNA sequence that is available for binding a second SPIA™ DNA/RNA
chimeric primer. DNA polymerase then initiates replication at the 3' end of the primer,
displacing the existing forward strand. The RNA portion at the 5' end of the newly synthesized
strand is again removed by RNase H, exposing part of the unique priming site for initiation of
the next round of cDNA synthesis. The process of SPIA™ DNA/RNA primer binding, DNA
replication, strand displacement and RNA cleavage is repeated, resulting in rapid
accumulation of cDNA with a sequence complementary to the original mRNA. WT-Ovation™
Pico products (NuGEN) are labeled using the FL-Ovation™ cDNA Biotin Module V2 (NuGEN).
Each labeled cRNA targets are synthesized according to manufacturer's protocols. The
quantity and quality of the amplified cRNA or cDNA were assessed by a ND-1000
spectrophotometer (Nanodrop Technologies), and Agilent Bioanalyzer (Agilent Technologies),
respectively.

16

Hybridization mixtures were prepared according to Affymetrix procedures to
accommodate 5 μg of cDNA targets from NuGEN amplification. Human Gene 1.ST platform
were hybridized, revealed and washed according to the Affymetrix protocol. Gene chips were
scanned using a 7 G scanner (Affymetrix) and images (DAT files) were converted to CEL files
using GCOS software (Affymetrix).
2.3 Cells and culture conditions
Cell lines were provided by Dr. John Minna (UT South Western, Dallas, TX) or
obtained from the the American Type Culture Collection (ATCC) and grown in RPMI media,
unless otherwise specified by the ATCC. The identity of each cell line was confirmed by DNA
fingerprinting by the Univeristy of Texas M.D. Anderson Cancer Center Characterized Cell
Line Core Service at the same time as total protein lysate preparation. Immortalized human
bronchial epithelial cells (HBEC3-KT) containing wild type and mutant KRAS were maintained
in K-SFM (Life Technologies Inc) media containing 50 μg/mL of Bovine Pituitary Extract (BPE)
(Life Technologies Inc.) and 5 ng/mL of EGF (epidermal growth factor) (Life Technologies Inc.)
as described previously81. All cell lines were mycoplasma tested by e-Myco kit (Boca
Scientific). MiaPa Ca-2 and HCT-116 and the isogenic variants lacking an oncogenic KRAS
were kindly provided by Dr. Natasha Ignatenko (University of Arizona, Tucson,AZ).
2.4 Preparation of protein lysates and reverse-phase protein array (RPPA).
For each cell line, protein lysate was collected from sub-confluent cultures after 24
hours (h) in media with 10% fetal bovine serum (FBS) (“full serum’), 0% FBS (“serum
starved”), or 24 h of 0% FBS followed by 30 minutes of 10% FBS immediately prior to protein
harvest (“serum added”). For total protein lysate preparation, media was removed and cells
were washed twice with ice cold phosphate buffered saline (PBS) containing Complete
protease inhibitor cocktail tablets and PhosSTOP Phosphatase inhibitor cocktail tablets (2
tablets each per 500mL PBS) (Roche Applied Science) and 1 mM Na3VO4. Lysis buffer (1%
Triton X-100, 50 mM HEPES [pH 7.4], 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM
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NaF, 10 mM NaPPi, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and 10
µg/mL aprotinin) was added to the cells and samples were vortexed frequently on ice for 20
minutes, followed by microcentrifugation at 14,000 rpm for 10 min. Cleared supernatants were
collected, followed by protein quantification using the BCA reaction kit (Pierce Biotechnology,
Inc.). Proteins and phosphoproteins were then quantified by reverse phase protein array
(RPPA), as previously described82. After quantification, data was logarithm transformed (base
2) for further processing and analyses. Then median-control normalization was applied on the
dataset. The statistical analyses were performed using R (version 2.7.0).
2.5 Immunoblots and immunoprecipitations
Cells were washed twice with ice-cold PBS and lysis buffer containing 50 mmol/L
HEPES (pH 7.5), 50 mmol/L NaCl, 0.2 mmol/L NaF, 0.2 mmol/L sodium orthovanadate, 1
mmol/L phenylmethylsulfonyl fluoride, 20 μg/mL aprotinin, 20 μg/mL leupeptin, 1% NP40, and
0.25% sodium deoxycholate. Protein concentration was determined by bicinchoninic acid
assay (Pierce Biotechnology) and 50 μg of cell lysate protein were boiled for 5 min with
denaturing buffer containing 0.25 mol/L Tris (pH 6.8), 35% glycerol, 8% SDS, and 10% 2mercaptoethanol, loaded on a 10% acrylamide/bisacrylamide gel, and separated by
electrophoresis at 150 V for 40 min. Proteins were electrophoretically transferred to a
nitrocellulose membrane; preincubated with a blocking buffer of 137 mmol/L NaCl, 2.7 mmol/L
KCl, 897 mmol/L CaCl2, 491 mmol/L MgCl2, 3.4 mmol/L Na2HPO4, 593 mmol/L KH2PO4, and
5% bovine serum albumin; and incubated overnight with anti–phosphorylated Thr308Akt,Ser473-Akt, anti-CRaf Ser 338 Mapk Thr202/Tyr204, p70 S6K Thr389 or anti-Akt. (Cell Signaling
1:1000), anti-CNKSR1 (Signal Transduction labs) anti-lamin A/C and anti–β-actin (Santa Cruz
Biotechnology1:2000Donkey anti-rabbit IgG peroxidase-coupled secondary antibody (GE
Healthcare) was used for detection). For measurement of active RalA and RalB, Ral and RalB
activation kits were used (Biorad). Band density was measured using the Renaissance
chemiluminescence system on Kodak X-Omat Blue ML films (Eastman Kodak).
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2.6 Viral vector construction
Vectors expressing wild type and mut-KRas-G12C and mut-KRas-G12D were
constructed from a previously described vector, pLenti6-KRAS-V1224, using a site-directed
mutagenesis kit (Stratagene) and transected into HBEC cells with stable siP53 as previously
described81. Correct sequences were confirmed by sequencing for all vectors. Infected cells
were selected with blasticidin (2 µg/ml) for 5 days. The cDNA of transformed HBEC3-KT cells
were sequenced to confirm presence of KRAS mutations.
2.7 Soft agar growth assays.
Soft agar-growth assays were performed as previously described81 seeding 1,000
viable cells in 12-well plates in triplicate and counting colonies after four weeks.

Each

experiment was performed in triplicate.
2.8 Molecular modeling
The HRas proteins in PI3K-HRas complex (1HE8) and RalGDS-HRas heterotetramer
complex (1LFD) were employed as templates to build wild-type, G12C and G12D KRas
models. The derived models were slightly minimized by NAMD and then molecular dynamics
(MD) studies were carried out as reported83. Parameters for GTP were generated as the
chimeric analog of ATP and guanine using CHARMM27. The system was solvated in a water
box in which every protein atom was at least 8Å away from the boundary of the box. Sodium
chloride at 100mM was added to neutralize the system charges. After 400ps for equilibrium,
we conducted 8ns MD simulations, and the trajectory was recorded every 200fs. Trajectories
for the last 6ns were evaluated and they were superimposed with WORDOM84. The average
structures were obtained and then followed with carbon-tethered energy minimization in MOE
to eliminate structural defects. The snapshots in every 100ps were used to calculate the
binding of KRas to PI3K and RalGDS using ZRNAK program85.
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2.9 Screening of compounds against isogenic mutant KRAS lines.
SW48 and the isogenic KRAS lines harboring G12D, G12C, and G12V were obtained
from Horizon Discovery labs on a one year lease. These cells were cultured in McCoys media
with 10% FBS to 80% confluency. Cells were then released from flasks via trypsinization and
plated into 96-well plates at an initial density range of 2000 cells per well. Cells were allowed
24 hours to attach, and then the following drugs were added to the culture media at a range of
concentrations from 0 – 5 µM: GSK60693, GSK1120212, MK2206, AZD6244 (produced at the
MDACC translational chemistry facility). Cells were incubated for 72 hours with the drugs, and
then viability was assessed using an MTS viability assay. Cells were exposed to MTS reagent
(Promega) dissolved in PBS (Hyclone) at a concentration of 200 µL reagent/mL media for 2
hours. Absorbance was then read at 490 nm, and viability was expressed as a percentage
normalized between the negative control (no cells plated) and the condition of cells with no
drug added (100% viability) normalized as the upper limit of viability.
2.10 Screening of compounds against NSCLC cell line panel.
Our panel of 30 cell lines and an extensive characterization were a generous gift from
Dr. John Minna (UTSW) All cell lines were cultured in RPMI 1640 with 10% FBS. Cells were
treated with concentrations of MK2206 and AZ6244 at concentrations 0.01 to 50µM and
evaluated for as described above. IC50’s were determined using Excelfit.
2.11 siRNA screening
MiaPaCa-2 and M27 were confirmed mycoplasma negative by the siRNA screening
service at MD Anderson and maintained in DMEM with 10% FBS. Optimization was carried
out using in house optimization methods in house. A parallel screen was then carried out with
a genome wide siRNA library (Dharmacon)
2.12 Individual siRNA and plasmid transfection.
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For transfection in a six well plate, cells were plated at 100,000 cells per well in 2mls
media and allowed to attach overnight. Per well 5µl of Dharmafect 2 (Dharmacon) was added
to 200µl OptiMEM (Gibco) and 4µl of the siCNKSR1 smartpool Dharmacon (M-012217-010020) or individual siCNKSR1 siRNAs (Qiagen SI02665411) was added to 200µL to OptiMEM
in parallel and allowed to sot for 5 minutes. These tubes were mixed and incubated at room
temperature for 20 minutes. 1.6 of the appropriate media was then added to this mixture. and
then media in the wells removed, This mixture was then added to the cells in a dropwise
fashion and the cells were incubated for 48-72 hours. For the GFP control and CNK1 PH
domain plasmids 175,000 cellsper well plated in a 6 well plate. Per well 2.5µl of lipofectamine
2000 (Gibco) and 125µl of OptiMEM were combined and 2.5µg of the appropriate plasmid and
125µl of OptiMEM were combined in separate tubes and allowed to incubate at room
temperatue for 5 minutes. These two tubes were then combined and allowed to incubate for
20 minutes. 200µl of this mixture was then added to 1ml of fresh media already in the
appropriate well and allowed to incubate for 5 hours. The transfection efficiency was
determined through the expression of GFP after 24 hours and the cells were counted with a
hemocytometer after 72 hours to determine viability.
2.13 Spheroid formation
The plates were optimized for the best cell density and found to be 20,000 cells per
mL. The lid was removed from a a 96-well Greiner plate and turned upside down. 20 uL of the
20,000 cells per mL suspension was then added directly into the middle of the circles found on
the lid of the 96-well plate forming a small drop. 100 uL of media was added into the
corresponding wells, used to maintain the temperature of the drops, and the lid was flipped
back over carefully placing it back onto the plate without disturbing the drop. The plate was
then placed into the incubator for 3 days to allow the cells to migrate to the bottom of the drop
due to gravity. After 3 days, 400 uL of media was added to the corresponding wells a SCIVAX
96-well plate. The lid from the Greiner 96-well plate was removed and placed onto the SCIVAX
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plate allowing the drop to come in contact with the media and placed back into the incubator.
After one hour, 200 uL of media was removed from the corresponding wells carefully without
disturbing the spheroid and imaged.
2.14 Anoikis assay
Transfected cells were grown to sub-confluence in 75-cm2 tissue culture flasks. For
cultures in suspension, cells were detached from the tissue culture flasks using 0.25% trypsinEDTA (Invitrogen). Once detached, cells were cultured in complete medium on a six-well plate
(5 × 105 per well) coated with Ultra Low Attachment Surface (Corning,) for defined hours. The
growth rate of cells in suspension were measured using the trypan blue exclusion assay and
the viability was measured quantitatively using the Cell Death Detection ELISA (Roche), by
detecting cytoplasmic histone-associated DNA fragments (mono- and oligo-nucleosomes)
after induced cell death. Briefly, anti-histone antibody is fixed in 96-well plate. After cells
harvested, the number of cells needed for the assay was retained (1x 105 cells) and lysed.
Then, lysed samples were loaded onto plates and after 90 min of incubation, conjugated
solution (diluted anti-DNA peroxidase antibody) is pipetted into each well. After further
incubation of 90 min, wells are washed and substrate solution containing ATBS (2,2’-azino-di[3-ethylbenzthiazoline sulfonate]) is added. The plate is read in a plate-reader (Fluostar
Omega, BMG Labtech) at 405 nm and 490 nm (reference wavelength), and the data is
expressed as absorbance 405-490 nm.
2.15 Cell cycle analysis
0.7 mL of ice cold 100% ethanol was added to 1 x 106 stained cells contained in 0.3
mL cold PBS then incubated overnight. The sample was then centrifuged and the supernatant
removed. 250 µL of 500 units/mL Rnase in PBS with 1.12% sodium citrate was added to the
cell pellet. The sample was then vortexed gently and incubated at 37°C for 30 minutes. 250
µL of propidium iodide (Sigma) at 50 mg/mL was then added to the sample and the cells were
22

incubated at room temperature for at least 1 hour in the dark. Finally the samples were read
on the facility flow cytometer
2.16 Confocal imaging
HEK293T cells were co-transfected with CNK and either wild type or G12D mutant
KRAS. 24 hours post-transfection, cells were seeded on glass coverslips and allowed to grow
a further 24h and then serum deprived overnight. Cells were fixed with 4% (w/v)
paraformaldehyde pH 8.0 for 20min at room temperature. Following 6-7 washes with PBS
(pH8.0) the coverslip was mounted onto a slide with mounting medium (0.1% pphenylenediamine/75% glycerol in PBS at pH 7.5–8.0). Confocal laser scanning microscopy
was performed with a Leica SP5 confocal microscope system with 63X oil-immersion objective
(numerical aperture NA=1.4), a line scan speed of 600 Hz, with image size of 1024x1024
pixels. GFP was excited with an argon-visible light laser tuned to 488 nm, mRFP were excited
with a krypton laser tuned to 543 nm. GFP and RFP fluorescence emissions were collected
using a photomultiplier tube via 514/10 nm and 595/10 nm band selections respectively.
2.17 Fluorescence lifetime imaging microscopy (FLIM)
FLIM experiments were carried out using a Leica TCP SP5 inverted advanced confocal
microscope system with internal photomultiplier tube (PMT) detector for TCSPC (timecorrelated single-photon counting). The sample was excited with a tunable femtosecond (fs)
titanium-sapphire laser with repetition rate of 80MHz and pulse width less then 80fs (Spectral
Physics, Mai Tai BB). The wavelength used for two-photon excitation was 930 nm and the
fluorescence was detected through a 525±25 nm interference filter. Images were obtained with
oil-immersion objective (numerical aperture NA=1.4), a line scan speed of 400 Hz, with image
size of 512x512 pixels. For FLIM analysis the pixels were reduced to 256x256. FLIM data was
collected using Becker & Hickl SPC830 data and image acquisition card for TCSPC. The
fluorescence decays were fitted with a single exponential decay model using Becker and
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Hickl's SPCImage software and the GFP fluorescence lifetimes were displayed in a false
colour map.
2.18 Surface plasmon resonance spectroscopy binding assays
All interaction analyses were done with a Biacore 3000 Control Software v3.2, and
BIAevaluation v4.1 analysis software (Biacore). The PH domain His-fusion proteins (CNK1
and AKT1) were expressed at the Center for Biomolecular Structure and Function at MD
Anderson and immobilized on a NTA chip to a level of 10,000 response units or less. Small
molecule analytes at concentrations ranging from 50µM to 0.010 µM were injected at a high
flow rate (30 μL/min). DMSO concentrations in all samples and running buffer were 1-5% (v/v)
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KRas effecter utilization is determined by the type of activating mutation
3.1 Introduction
A number of previous studies have suggested that the method by which KRAS is
activated may influence the behavior of cancer cells or patient prognosis

64

. The first studies

after the identification of mutant Ras in human patients defining the transforming properties of
these performed by Levinson et al found differences in transformation dependent on the
identity of the amino acid substituted at codon 12 and postulated that different amino acids
activating Ras may have different biological outcomes57. Early work in the determining crystal
structures for the transformed Ras proteins additionally found that the flexibility of the switch II
region, responsible for interacting with effecters in the protein was determined by the identity
of the substituted amino acid 86. Subsequent to this work, the multi-center international
RASCAL trial, aimed at definitely defining KRAS mutation as a poor prognostic event in
colorectal cancer, found that those patients with KRAS activated by a G to T nucleotide
substitution (resulting in a glycine to valine or cysteine amino acid substitution) resulted in a
worse prognosis for patients 87. These results were later validated in the RASCAL II trial 88.
Small studies later suggested differences in cellular invasive capacity 89 and tumorgenicity
based on both the identity of the amino acid activating the protein90 and the codon location of
the substitution91. Murine tumor models characterizing the effects of activated KRAS
specifically in the lung have largely focused on the KRas G12D 69,79 substitution although this
alteration is more predominant in human colon and pancreatic cancer than in human lung
cancer22. The most common activating mutation in human lung tumors, a KRas G12C amino
acid substitution, has been made in a lung specific fashion in a mouse model but displayed a
strikingly different phenotype resulting in a longer time to tumor development than the KRas
G12D model displaying a decreased frequency of progression 92. Notably in murine cells
activating KRas mutations showed inconsistences in the activation of the expected KRas
effecter pathways with the KRas G12D mutant mice having lowered but constitutive Akt
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activation66 while both KRas G12C and KRas G12V lung models having no detectable Akt
activation92,93. These observations led to our hypothesis that different activating KRAS
mutations may have different responses to targeted therapies due to different signaling
outputs elicited by the different signaling cascades.
In the BATTLE trial conducted at MD Anderson no association was found between
KRAS mutations and the targeted therapies used in the trial adding to a conflicted body of
literature that showed an inconsistent association between KRAS and various trials with
targeted therapies. However, when we reexamined the data by looking at the amino acid
substitution which activated KRAS a significant association was found between a C or V
substitution at KRas codon 12 and decreased response to targeted therapies measured by
progression free survival with the strongest association found seen with sorafenib. We then
looked across a large number of lung cancer cell lines and also expressed the different forms
of activated KRAS in immortalized human bronchial epithelial cells we observed differential
activation of KRas effecter pathways. Finally using the crystal structures of HRas to create a
homology model of KRas and comparing the effects of KRas interaction with different effecters
we were able to show how different substitutions impacted KRas binding to effecters.
3.2 Results
3.2.1 Patients with different forms of oncogenic KRAS vary in their response to targeted
therapies
The BATTLE-1 trial for patients with refractory NSCLC was conducted at MD Anderson
between November 30, 2006 and October 28, 2009. Patients received either erlotinib,
vandetanib, bexarotene and erlotinib, or sorafenib and were additionally tested in mandatory
tumor biopsies for markers thought to be associated with response to these agents94. Using
these criteria, the BATTLE-1 data was reanalyzed for the effect of different mut-KRas amino
acid substitutions on patient progression free survival. There were 258 evaluable patients and
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the primary endpoint was 8-week disease control rate, with patients being treated until disease
progression or unacceptable toxicity. There were 46 total KRas mutations with 43 95 at codon
12, and no codon 13 mutations. We found that mut-KRas G12C/ V was associated with overall
decreased patient progression free survival compared to other mut-KRas (mostly G12D), or
WT-KRas (P = 0.046). The negative prognosis conferred by the C or V substitution was most
pronounced in the sorafenib treatment arm (P = 0.026) (Figure 4) This is the first indication in
NSCLC of different amino acids substitutions within mut-KRas influencing patient response to
targeted therapy in lung cancer.

3.2.2 Gene expression analysis in patients with different KRAS activating mutations
We next analyzed patient gene expression profiles using tumor biopsies from mutant
KRAS patients to determine which gene probes were responsible for the greatest variation.
Using these probes we were able to observe the genes which most accurately defined the
differences between the two KRAS groups by applying a false discovery rate of 0.3. These
probes are displayed in the heat map (Figure 5). The genes probes which showed the
greatest variation were primarily involved in cell cycle regulation, particularly mitosis. These
gene probes included Polo Like Kinase 1 (PLK1) which triggers the G2/M transition through
the phosphorylation and subsequent activation of the Cdc25c phosphatase which
dephosphorylates and activates the Cyclin B/Cdc2 complex, the primary cyclin complex
involved in mitosis Additionally both Cyclin B1 and Cyclin B2 expression were upregulated in
those patients without a G12C/V mutation which predominantly consisted of G12D
substitutions. The observation that these cell cycle proteins are up regulated in KRas G12D
tumors is significant in regards to two previous studies. The first is the finding that KRas G12D
selectively drives cell cycle progression in a mouse colon model while NRas G12D selectively
promoted inhibition of apoptosis 66. The second is that a KRas G13D driven colon line was
found to be selectively sensitive to knockdown of genes coding components of the mitotic
machinery including Plk1when compared with an isogenic line with a silenced mut-KRAS allele
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when a genome wide shRNA screen was performed, 96. These BATTLE microarray results
indicate that these results may not be universal for oncogenic KRAS but specific for the
aspartate substitution.
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Figure 4

Figure 4: Progression free survival in response to targeted therapies by KRas G12C/V
amino acid substitution. Patients were evaluated for progression free survival to targeted
therapies by the presence of any activating KRas mutation, and then by the presence of a
G12C or G12V mutation or other KRas mutations (mostly G12D). Analysis of patients treated
with sorafenib by type of KRas mutation. Patients with a wild type KRas or mutations other
than G12C or G12V had significantly longer progression free survival when treated with all
targeted therapies and sorafenib. Reprinted with permission from 97
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Figure 5

Figure 5: Microarray of BATTLE patients with mutant KRas. Heat map of non-supervised
clustering of the expression of the top genes between patients with KRAS G12C or G12V and
other activating KRas mutations. Patients with G12C or G12V mutations had lower expression
of cell cycle proteins associated with mitotic progression including PLK1 and CCNB1 and
CCNB2 (Cyclin B1 and Cyclin B2). Reprinted with permission from 97.
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3.2.3 Oncogenic KRAS signaling across a panel of lung cancer cells
To explore the differences in signaling activities through a comprehensive analysis of
protein signal transduction we conducted reverse phase protein array (RPPA) analysis across
a panel of 58 genetically characterized NSCLC cell lines comparing mut-KRas-G12C/ V, other
mut-KRas and WT-KRas . The cell lines were grown under three conditions as it is unclear
which best recapitulates an in-vivo environment: cells maintained in 10% serum, cells that
were starved of serum for 16 hours and cells starved of serum for 16 hr and then serum added
back for 30 minutes. The Ras effecters measurable by RPPA were then observed (Figure 6).
The KRas effecter Raf activates Mek resulting in cellular proliferation and survival 36. while
p38 is activated by the Ras effecter Tiam1 and has a diverse set of cellular functions 98
Analysis of these proteins showed neither active Mek or p38 showed significant activation
differences between the KRas mutant groups or between cell lines with activated KRas and
wild type KRas cell lines. In contrast, the target of the Ras effecter PI3K, Akt showed
decreased activation measured by phospho-Akt relative to WT-KRas cells in mut-KRas-G12C/
V cells, and elevated in the remaining mut-KRas cells (Figure 6). These findings were
confirmed by Western blot analysis in a smaller set of NSCLC cell lines with KRas codon 12
mutations (Figure7). Additionally a subset of genes involved in the Akt signaling pathway
were analyzed to determine if signaling was decreased across the entire PI3K-Akt axis or
localized to Akt itself. The data from cell lines in our panel of NSCLC lines with mutant KRAS
were subjected to hierarchical clustering based on activation of the Akt and mTOR signaling
and revealed that while Akt and its effecters were down regulated, mTOR known to be
activated by Akt signaling99 ,was at levels comparable to wild type KRas or other activating
KRas mutations (Figure 8) Thus in NSCLC cell lines differences in activation of KRas
effecter signaling, with mut-KRas G12C/V displaying significantly less Akt activation than
other KRas activating mutations, suggesting that mut-KRas G12C/V cells may not activate
PI3K as efficiently as other forms of activate KRas.
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Figure 6

Figure 6: Signaling through KRas effecter pathways in a panel of NSCLC cells. Activation
of Ras pathways measured by RPPA of phosphorylated Mek, p38, and Akt in cells grown in
serum, in serum free media for 16 hours, or in serum free media followed by an acute 30
minute exposure to 10% serum. Mutant KRas G12C/V, other forms of mutant KRas and Wild
type KRas were compared. Activated Akt (phospho-ser473) was significantly reduced in
mutant KRas G12C/V when compared to other forms of mutant KRas of wild type KRas in
serum or serum free conditions while other forms of mutant KRAS showed higher Akt
activation. Reprinted with permission from 97.
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Figure 7

Figure 7: Validation of RPPA findings in a panel of lung cancer cells. Activation of Akt
was measured at Akt thr308 and Akt ser473 across a panel of lung cancer cells stratified by
KRas status. Akt was reduced in mutant KRas G12C/V. Mapk activation was additionally
measured by phosphorylation of Mapk thr202 and Mapk tyr204 but showed no pattern of
activation with the method of KRas activation. Actin served as a loading control. Reprinted with
permission from 97.
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Figure 8

Figure 8: Heatmap of Akt pathway activation. The Akt/mTOR pathway components
available on the RPPA organized into a heat map with mutant KRAS annotation at the top. As
had been observed previously Akt activation was lower in the mutant KRas G12C/V and this
was mirrored by activation of the direct Akt effecters GSK and TSC2 as measured by
phosphorylation. In contrast, multiple mutant KRas G12C/V lines showed activation of the
mTOR effecters p70 S6K and 4EBP1 as measured by phosphorylation. Reprinted with
permission from 97.
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3.2.4 Oncogenic KRAS expressed in HBEC cells
To confirm the findings in a uniform cellular background, the most common mut-KRas
in CRC, G12D; the most common mut-KRas in NSCLC, G12C; and WT-KRas were introduced
into previously characterized immortalized human bronchial epithelial cells 81 with P53
knockdown (HBECsiP53), as p53 has been shown to induce apoptosis as a result of cellular
stress in Ras transformed cells 100 . Plasmid DNA was extracted from the cell lines and KRas
was sequenced to ensure that the correct mutt-KRas was present (Figure 9). Additionally
elevated levels of KRas protein were seen in the transfected lines. The oncogenic KRas G12D
HBECsiP53 cells with the highest Akt activation of the four lines indicating increased
activation of the KRas effecter PI3K (Figure 10). In contrast, the KRas G12C mutants had
blunted Akt signaling representing the lowest of the four lines. Despite these differences the
levels of activated p70 S6K, an indicator of mTOR activity, remained constant between these
lines. Additionally, extracts from the four lines were incubated with beads with the Ral binding
domain of the shared effecter of RalA and RalB proteins, RalBP (Figure 11). In contrast to
what was seen with Akt activation, KRas G12D had the lowest RalA and RalB while KRas
G12C and overexpressed KRas WT had the highest. This pattern of signaling is consistent
with what was observed previously when these mutations were introduced into the lungs of
mice, where mut-KRas G12D induced Raf and Akt activation when expressed both
endogenously and ectotoapathally 60 while mut-KRas G12C resulted in only Raf and Ral
activation, with minimal Akt activation regardless of expression level92,101.
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Figure 9

Figure 9: Validation of transfection and expression of wild type and mutant KRAS
plasmids in immortalized bronchial epithelial cells (HBEC). Sequencing of plasmids
extracted from HBEC cells and measured of KRas protein in HBEC cells. Reprinted with
permission from 97.
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Figure 10

Figure 10: Expression of Akt and Mapk pathway activation in HBEC cells. Activation of
the Akt and Mapk pathways were measured in HBEC cells by the expression of
phosphorylated proteins. Akt activation was higher in KRas G12D when compared to WT or
KRas G12C as had been seen in a panel of cell lines in Figure 6. No differences were seen in
the activation of Mapk or p70 S6K. Reprinted with permission from 97.
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Figure 11

Figure 11: Activation of Ral A/B by KRas. Ral activation was measured in different forms of
KRAS transfected HBEC cells. Conversely to Akt activation, both RalA and RalB were most
active in HBEC cells with either overexpressed WT or mutant KRas G12C transfected. KRas
G12D transfection showed a low level of Ral activation with levels comparable to vector
control. Figure Reprinted with permission from 97.
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3.2.5 Behavior of different activating KRAS mutations in growth assays
In addition to studying the effects of these different KRas mutants on downstream
signaling, studies were performed to determine to effects of different activating KRAS
mutations on cell growth. We performed a growth assay on these cells in culture and
surprisingly found that despite the differences among effecter signaling cascades we had seen
our cells with activating KRAS mutations or overexpressed wild-type KRAS the cells grew at a
similar rate, and initially at a rate similar to our cells transfected with only the vector (Figure
12). The primary difference observed was when these cells approached confluence, those
cells with vector control stopped growing, while the addition of overexpressed wild type or
mutant KRas abrogated this growth arrest. This is consistent with the reports of elevated KRas
signaling abrogating cell-cell contact mediated growth inhibition in early reports of HRAS
transformed cells 70. We also looked at the ability of these cells to form colonies in an
anchorage independent growth assay. We found that the HBECsiP53 cells with
overexpressed wild type or mutant KRAS were able to form colonies more effectively than the
vector alone cells (Figure 13). However, our cells with oncogenic KRAS mutations were able
to form more colonies than the cells expressing wild type KRas and additionally the mutant
KRas G12C mutation formed more colonies in the assay than mutant KRas G12D despite
displaying sharply reduced PI3K- Akt signaling. As the KRas G12C cells had elevated Ral
signaling, this observation may reflect the reported effects of Ral mediating Ras induced
anchorage independent growth102.
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Figure 12

Figure 12: Growth of Cultured HBEC siP53 cells with vector or KRAS transfects. In a
standard growth assay (96 well tissue culture dishes, 10% FBS) Both the primary p53 deleted
HBEC’s and the transfectents grew at a similar rate. At Confluence (~60 hours) the vector
control began to decline in growth rate while the wild type and mutant KRAS transfects
continued to grow. Reprinted with permission from 97.
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Figure 13

Figure 13: Clonogenic Assay with HBEC siP53 cells. In clonogenic assays performed with
HBECs transfected with different forms of oncogenic KRAS, a higher number of clones were
seen with the transfection of either a mut-KRas G12D or G12C than a wildtype or vector
transfection while the KRas G12C HBEC line formed significantly more colonies than any of
the other lines tested. Reprinted with permission from 97.
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3.2.6 Effect of different forms of oncogenic KRAS on growth factor signaling
Our observations that both KRas G12C NSCLC cell lines in our panel and KRas G12C
transfected HBEC cells lacked Akt activation even in the presence of growth factors present in
serum was intriguing as growth factors are capable of activating this signaling cascade in a
KRas independent fashion. We had previously observed the KRas G12C/V patient tumors
showed repressed activity through the proximal Akt pathway, although many lines with minimal
Akt activation showed robust activation of mTOR effecter proteins. The p70 S6 kinase, an
output of mTOR, has been shown to exert a feedback to restrict growth factor signaling to the
Akt pathway and this led us to postulate that this may be a contributing factor to our lack of
observed Akt activation 103. To address this, we first observed the baseline levels of activated
p70 S6K in our panel of cell lines. Analysis of phosphorylation the mTOR effecter p70 S6K
revealed no significant difference between these groups under serum or serum deprived
conditions and surprisingly under conditions of acute serum stimulation cells with KRas G12C
or G12V had significantly higher phosphorylated p70 S6K (Figure 14). HBEC KRas G12C or
G12D activating mutations were treated with rapamycin an inhibitor of mTOR and, thus, of
p70S6K signaling. In the mut-KRas G12C HBEC cells inhibition of p70S6K resulted in a
robust increase in p-Akt (Figure 15). This was additionally seen in all the cell lines tested from
the NSCLC panel (Figure 16). In contrast in KRas G12D lines which already showed p-Akt,
rapamycin resulted in only a slight further increase in Akt signaling both in HBEC G12D
transfects and cell lines from the NSCLC panel harboring G12D or G12R. Cells with a
mutationally activated EGFR showed no increase in phosphorylated Akt when treated with
rapamycin. Thus the results indicate that KRas driven mTOR signaling is inhibiting the Akt
activation which would occur through growth factor activation in cells with a KRas G12C
mutation.
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Figure 14

Figure 14: RPPA measurement of the mTOR effecter p70 S6K. p70 S6K was measured in
either serum, serum free or acute serum stimulation conditions as described previously.
Despite lower levels of activated Akt in the mutant KRas G12C/V group under serum or serum
free conditions (Figure 6) no significant difference was observed in activation of the mTOR
effecter p70 S6K as measured by phosphorylation. In contrast, p70 S6K activation was
significantly higher in cells with serum acutely added. Reprinted with permission from 97.
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Figure 15

Figure 15: Mutant KRas G12 C/V restrains Akt signaling through mTOR mediated
repression of growth factor signaling in HBEC cells. HBEC cells were treated with 0.5 µM
of the mTOR inhibitor rapamycin. In cells with overexpressed WT or G12C KRas showing no
expression of active Akt at baseline, an activation of Akt signaling was observed. In the vector
control or G12D KRas where Akt was observed to be activated at baseline, only a marginal
further increase in Akt activation was observed. Reprinted with permission from 97.
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Figure 16

Figure 16: Mutant KRas G12 C/V restrains Akt signaling through mTOR mediated
repression of growth factor signaling in NSCLC cell lines. Various NSCLC cell lines were
treated with 0.5 µM of the mTOR inhibitor rapamycin. In cells with G12C KRas showing no
expression of active Akt at baseline, an activation of Akt signaling was observed. In other
mutant KRas lines or an EGFR mutant line, Akt was observed to be activated at baseline, only
a marginal further increase in Akt activation was observed. Reprinted with permission from 97.
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3.2.7 Computer modeling of different forms of oncogenic KRas
Finally, we performed molecular modeling studies of the KRas protein using the
available crystal structures of HRas (~95% sequence identity to KRas) to create homology
models of mut-KRas G12D and G12C, followed by molecular dynamics for structural
refinement. KRas interacts with its different downstream effecters by undergoing large
conformational changes in the switch I and switch II regions of the protein surrounding codon
12 and 13 amino acids. When bound to PI3K the switch II regions of mut-KRas G12C and WTKRas exist in a similar conformation that exposes the bound GTP for hydrolysis, thus,
inhibiting KRas activity. In contrast, the introduction of the aspartate side chain results in
electrostatic repulsion which pushes the y-phosphate in the GTP nucleotide towards the
Thr35 residue in Switch I, weakening the H-bond between the y-phosphate of Gly60 (in
Switch II) in particular. This creates a pocket for Gln61 side chain, and forms H-bonds
between OE1 of Gln61 and HN in Gly60, whille Gln61 amine group binds to y-phosphate.
PI3K and Ral compete for activation by KRas although the way in which KRas activates Ral is
dramatically different to PI3K, with two KRas molecules forming a homodimer to facilitate
RalGDS binding. The Y32 of one KRas interacts with GTP in the other KRas and is critical for
RalGDS activation20 (Figure17). Our modeling shows that in mut-KRas G12D the bulky D
pushed aside the Y32 preventing homodimer formation and Ral activation. In contrast, the
smaller C of mut-KRas G12C enhances homodimer formation and Ral activation. Both
molecular dynamic and protein-protein docking data show the results of these changes with
mut-KRas G12C having a higher affinity for RalGDS and mut-KRas-G12D preferring PI3K
(Figure18).
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Figure 17

Figure 17: Computer modeling of different substitutions at codon 12 in the KRas
protein. A homology model of KRas was created from the publically avaliable crystal structure
of HRas. This structure was then applied to docking models with PI3K and RalGDS. These
structures revealed that an aspartate at codon 12 contorted the key Q61 and Y32 regions of
KRas due to interactions with the gamma phosphate of bound GTP. This new conformation
stabilized GTP binding when KRas was bound to PI3K. In contrast, the new conformation of
Y32 inhibited the ability of KRas to form the tetramer necessary for RalGDS interaction.
Reprinted with permission from 97.
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Figure 18

Figure 18: Scoring of different forms of mutant KRas bound to effecters. Z ranking was
used to determine the binding of KRas to different effecters. The highest Z rank score was
found for binding of KRas G12D into the RalGDS binding model, while WT and G12C KRas
showed similar scoring. Additionally, a comparison of PI3K and RalGDS binding revealing that
G12C showed more favorable binding to RalGDS than to PI3K accounting for our observations
in cells. Reprinted with permission from 97.
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Discussion
The recently completed BATTLE trial for patients with refractory NSCLC receiving
either erlotinib, vandetanib, bexarotene and erlotinib, or sorafenib found that total mut-KRAS
did not predict for overall survival for any of the treatments 94. Reanalyzing the BATTLE data
for the effect of different oncogenic KRas amino acid substitutions on patient survival revealed
that a cysteine or valine substituted for glycine at codon 12 in KRas but not all forms of mutant
KRas in a single group predicted for progression free survival. This is the first indication in
NSCLC that different amino acids substitutions of in oncogenic KRas influence patient
response to targeted therapy. A previous study in colon cancer patients reported that a
cysteine or valine substitution at the codon 12 position in KRas is associated with rapid tumor
progression and decreased patient survival when compared to other oncogenic KRas
substitutions (mostly G12D) or wild type KRas87,88. Analysis of microarray transcriptome data
in patient tumors from the BATTLE trial to find genes whose expression was significantly
different between G12C or G12V KRas mutants and other KRas mutants identified cell cycle
regulators such as Plk1 and Cyclin B1 as being down regulated in the oncogenic KRas G12C
or G12V tumors and up regulated in the remaining mutt-KRas tumors. Dysregulation of the cell
cycle is a well characterized feature of KRas mediated tumorgenesis 66. RPPA analysis of a
panel of genetically characterized NSCLC cell lines, comparing oncogenic KRas G12C or
G12V to other oncogenic KRas mutants and wild type KRas showed decreased phospho-Akt
in mut-KRas G12C or G12V cells, and elevated phospho-Akt in the remaining cells harboring
an oncogenic KRAS relative to those cells expressing wild type KRas. Transfection of
immortalized, p53 deficient human bronchial epithelial cells (HBEC siP53) with different forms
of oncogenic KRAS showed that cells expressing oncogenic KRas G12C decreased phosphoAkt but elevated levels of Ral A/B in the GTP-bound active form. In contrast, cells expressing
oncogenic KRas G12D showed increased phospho-Akt levels and decreased Ral activation,
compared to wild type KRas cells. All the KRAS transfected cells grew at a similar rate in
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culture but those with any form of KRAS transfected showed post-confluent growth. In contrast
oncogenic KRas G12C cells with lower Akt signaling but elevated Ral signaling exhibited
increased anchorage –independent growth in a colony formation assay compared to
oncogenic KRasG12D cells or cells expressing the vector control or a wild type KRas . These
findings agree with previous studies that found that Ral preferentially induces anchorageindependent growth in human cells, while Akt or Mek activation has few discernible effects 104.
The pattern of signaling is also consistent that previously observed when the same mutations
were introduced into the lungs of mice, where oncogenic KRas G12D induced Raf and Akt
activation 60as opposed to KRas G12C which resulted in only Raf and Ral activation, with
minimal Akt activation regardless of expression level 92,101. Many NSCLC cell lines with
minimal Akt activation displayed high activation of the mTOR effecter proteins p70nS6K and
4EBP. Inhibition of mTOR with rapamycin in cells with oncogenic KRas G12C resulted in the
inhibition of p70S6K and a concurrent increase in Akt activation. The translational regulator
mTOR is known to be activated by Akt signaling, in addition to the Mapk and Ral pathways 105.
Additionally, p70 S6K an output of mTOR has been shown to exert feedback to restrict growth
factor signaling to the Akt pathway. Our results suggest that KRas driven mTOR signaling is
inhibiting Akt activation which would otherwise occur through growth factor stimulation 103.
KRas is known to interact with different downstream effecters by undergoing large
conformational changes in the switch I and switch II regions of the protein surrounding the
codon 12 and 13 amino acids6. Our molecular modeling studies showed that oncogenic KRas
G12C weakens the interaction with PI3K while the bulky aspartate of oncogenic KRas G12D
causes steric interference of RalGDS homodimer formation and RalGDS activation which is
not seen with the Cys of oncogenic KRas G12C. Both molecular dynamic and protein-protein
docking data show the results of these changes, with a KRas G12C substitution having a
higher affinity for RalGDS, and KRas G12D a higher affinity for PI3K. These modeling results
are in agreement with the results of our cellular studies of the effects of the different oncogenic
KRas amino acid substitutions on signaling activities. The findings of our study are
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summarized in Figure 19 showing different mechanisms for signaling through wildtype KRas,
oncogenic KRas G12D and KRas G12C. The observation that the substitution of different
amino acids induces heterogeneous behavior in the KRas protein resulting in different
signaling outputs has profound implications for identifying and treating KRas driven tumors
Subsequent studies on a lung cell line with different forms of activated KRAS expressed from
a plasmid showed that different KRAS mutants conferred different sensitivities to both
cytotoxic and molecularly targeted agents in cell growth assays 106. The clear implication is
that it may be possible to better treat oncogenic KRAS driven by a particular activating amino
acid through an inhibitor to the particular pathways or to combine these agents in a rational
fashion.
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Figure 19

Figure 19: Scheme of signaling by different forms of KRas. WT-KRas and Akt are
activated by growth factors and can activate the Akt, Ral, and Mek pathways which can then
engage mTOR signaling and the mTOR effecter p70 S6K which then acts as a “feedback” to
shut off growth factor mediated signaling. Mut-KRas G12D activates Mek, Akt and mTOR
signaling independently of growth factors. Mut-KRas G12C actives Mek, Ral, and mTOR
signaling independently of growth factors and inhibits growth factor mediated activation of Akt
signaling. Reprinted with permission from 97.
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Targeting KRAS mutant tumors by inhibition of downstream effecters
4.1 Introduction
Since the clinical failure of the FTI’s, a majority of attempts to inhibit KRAS oncogene
driven tumors have not focused on the inhibition of KRas itself but have explored methods to
target mutant KRas indirectly 70. The first is to inhibit KRas downstream effecter signaling that
may be critical for the growth and survival of tumor cells with an activated KRas. The two
most studied effecter pathways for which agents are clinically available, Raf/Mek and
PI3K/Akt, have so far given equivocal results as to whether the approach will be successful.
The notable exception is that of B-Raf inhibitors in melanoma which have been shown to
activate Mapk signaling in cells with active Ras signaling 107. Mek has been identified as both a
KRas effecter critical for the Ras driven tumorgenesis 108 and, paradoxically, KRas has been
identified as a marker of resistance to Mek inhibitors109. In a similar fashion PI3K has been
identified as both critical for maintenance in tumors with oncogenic KRAS110 and oncogenic
KRAS has been identified as a resistance factor predicting lack of response to PI3K
inhibitors80. The observations presented in the previous chapter 97 suggest that the type of
amino acid substitution that actives KRas may influence which agents may be effective for
treatment, a concept that has been demonstrated both in cell culture models106 and in clinical
trials where in CRC KRas G13D mutation tumors are uniquely sensitive to the EGFR inhibitor
cetuximab 111. Alternatively, studies have also shown that the presence of additional oncogenic
lesions found frequently in human tumors, such as LKB1 loss in NSCLC, may complicate the
analysis. A transgenic mouse model with a mutant KRas G12D conditionally expressed in the
lung showed a response to a Mek inhibitor regimen, but the concurrent knockout of LKB1
reversed this sensitivity. To address the possibility that different activating KRAS mutations
were causing these discrepancies we utilized a set of isogenic colon cell lines for which the
parental line has a wild type KRAS, but gene editing had been used at the endogenous loci to
create an oncogenic KRas G12D, G12C, and G12V, and screened these cells against
clinically relevant inhibitors of Mek and Akt.. This approach eliminates artifacts which may
53

arise with the transfection of an expression vector, such as dramatic overexpression, and
interactions with the endogenous protein. Additionally we looked for correlations between the
methods of KRas activation in a 30 NSCLC cell line panel where additional high frequency
lesions are often present.
The second approach to discover a novel a treatment for KRAS driven cancer has
utilized broad siRNA and shRNA screening for synthetic lethal targets which inhibit the growth
of mutant KRAS cells. This approach in the hands of others has identified TBK1 as a
downstream effecter of RalB 112 , components of the cell cycle 96, and STK33, although it
should be noted some of these results have failed to be reproduced 113.
4.2 Results
4.2.1 Isogenic KRas G12C/D/V treated with targeted therapies
To determine if there is a single targeted therapy that could be effective against a
specific mutant KRAS we screened a large panel of cell lines against individual targeted
therapies already in clinical use. They were the Mek inhibitors AZ6244 and GSK1120212, and
the Akt inhibitors MK2206 and GSK 60693, using a panel of colon cancer cell lines with both a
wild type KRas, as found in the parental SW48 cell line, and the mutant KRas G12D, G12C,
and G12V substitutions created by gene editing at the endogenous loci. As the agents are
targeting the Mek-Erk and PI3K-Akt pathways, the levels of active Erk and active Akt were
measured by western blotting. Consistent with our observations in HBEC cells the SW48 cells
with wild type or a KRas G12D substitution had higher levels of active Akt than those with
KRas G12C or G12V substitution (Figure 20 ).Additionally, the SW48 KRas G12D cells had
higher levels of active Erk signaling which was not seen in our HBEC cells suggesting that
some effects of introducing different forms of activated KRAS may be cell type specific, or
differs when mutant KRas is expressed ectopically or at the endogenous location. Treatment
with the AZD6244 Mek inhibitor showed no clear trend in response, but treatment with the
Mek inhibitor GSK1120212 showed more consistent effects with the parental SW48 being the
most sensitive, followed by the mutant KRas G12C and G12V variants with SW48 KRas G12D
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being the least sensitive (Figure 21). The Akt inhibitor GSK60693 showed only weak effect
against the whole panel of cells with only the parental cell approaching 50% growth inhibition.
In contrast MK2206 an allosteric Akt inhibitor showed clear differences (Figure 22), inhibiting
SW48 wild type KRas growth the most followed closely by SW48 mutant KRas G12D then
G12C and G12V which never reached an IC50 value (shown in Table 1). This data indicates
that while each inhibitor will have unique efficacy, likely based on potency and pharmacology
that differences exist in the sensitivity of cells based on the substitution that activates KRas,
with mut-KRas G12C/V showing increased cell growth inhibition with Mek inhibition and mutKRas G12D showing a greater response to Akt inhibitors.
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Figure 20

Figure 20: Signaling through the Mapk and Akt pathways in SW48 colon cancer cells
with KRAS mutations substituted at the endogenous loci. The SW48 colon cancer cell line
had a WT KRAS allele substituted with a mutation resulting in a KRas G12D, G12C or G12V
protein. As we had observed in of HBEC cells KRas G12D activated Akt signaling while KRas
G12C or G12V showed weaker activation. In these cells KRas 12D also showed stronger
activation of the Mapk pathway.
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Figure 21

Figure 21: SW48 isogenic cell lines treated with Mek inhibitors. SW48 cells with WT KRas
substituted with KRas G12D, G12C, or G12V expressed from the endogenous loci were
treated with the indicated concentrations of the Mek inhibitors GSK1120212 or AZD6244 for
72 hours. In GSK1120212 treated cells wild type SW48 cells showed the greatest sensitivity
followed by KRas G12C/V while KRas G12D showed the least sensitivity. No clear pattern
emerged with AZ6244 indicating specific effects of these agents.
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Figure 22

Figure 22: SW48 isogenic cell lines treated with Akt inhibitors. SW48 cells with WT KRas
substituted with KRas G12D, G12C, or G12V substituted at the endogenous loci were treated
with the indicated concentrations of the Akt inhibitors GSK60693 or MK2206 for 72 hours. In
GSK60693 no clear pattern emerged. In MK2206 treated cells wild type SW48 cells showed
the greatest sensitivity followed by G12D, then G12C and G12V constant with the Akt pathway
activation observed in these cells. Again, agent specific effects were observed indicating nonequivalent pathway inhibition.
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Table 1
Cell Line

GSK1120212

GSK60693

MK2206

AZD6244

Wild type

1.53 µM

3.92 µM

1.92 µM

43.6 µM

12C

1.91 µM

None

7.82 µM

None

12D

3.91 µM

None

3.41 µM

136 µM

12V

1.82 µM

None

None

7.59 µM

Table 1: IC50 values for agents targeted to the KRas effecter pathways. All agents tested
against the SW48 isogenic lines had an IC50 >1 µM. SW48 KRas G12D was the least
sensitive to the Mek inhibitor GSK1120212 and the most sensitive to the Akt inhibitor MK2206
consistent with patterns of Akt signaling observed in the HBEC cell line in Chapter 3 and the
SW48 isogenic lines. GSK60693 and AZ6244 didn’t show this clear trend but also had greatly
reduced IC50’s for cell growth inhibition.
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4.2.2 Panel of lung cancer cells treated with targeted therapies
We also ran the Mek inhibitor AZ6244 and the Akt inhibitor MK2206 against a panel
of 30 characterized NSCLC lines and looked for associations between type of activating
KRAS mutant and response to these agents. No clear response pattern was seen in either the
isogenic lines or the panel of NSCLC cells for the Mek inhibitor AZ6244 (Figure 23). The
sensitivity of cell lines with activating substitutions in KRAS ranged from 3.4 µM to greater than
50 µM. Of the three lines most sensitive to AZ6244 (IC50<10µM) with oncogenic KRAS, the
two cell lines harboring KRas G12C had concurrent inactivating mutations in the tumor
suppressor STK11 (LKB1), previously identified in a mouse model to confer resistance to
tumor cells harboring oncogenic KRAS to this inhibitor69. Of the four cell lines most sensitive to
MK2206 (IC50 < 3µM) two had an inactivating LKB1 mutation without a concurrent KRAS
mutation (the only two on the panel) and H2122 a cell line with a KRas G12C substitution
coexisting with a LKB1 mutation showed sensitivity to MK2206 while other LKB1 mutant cells
with concurrent mut-KRas showed a marked resistance towards Akt inhibition (Figure 24).
The function of LKB1 in normal physiology is to stabilize and activate TSC2, which prevents
mTOR mediated translation under low energy (low ATP) conditions (Figure 26). The Mek and
Akt pathways are both capable of degrading TSC2 to promote transcription, but LKB1
activation prevents this 99. Measuring protein levels in LKB1 mutant cells sensitive to Akt
inhibition showed MK2206 treatment restored TSC2 levels suggesting Akt is responsible for its
degradation. In cell lines resistant to MK2206 the Mek inhibitor restored TSC2; however these
lines were not sensitive to Mek inhibition (Figure 25). This data suggests that unlike our
isogenic colon lines in NSCLC cell lines interplay between LKB1 loss and KRas activation
must be accounted for when attempting to predict response to targeted therapies and this may
be reflective of a number of secondary mutations.
Overall, the data suggest that at the present time our knowledge of the interplay of
signaling pathways activated by mutant KRas is inadequate to explain the differences in drug
sensitivities for these downstream signaling pathways, except perhaps when LKB1 loss of
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function and mutant KRas occur as independent lesions, as in our controlled models.
Additionally, two dimensional growth on plastic surfaces may be unable to pick the
dependence of mut-KRas cells on particular effecter pathways that are seen under conditions
of in anchorage independent conditions or in the tumor environment. We have already seen
this with the HBEC cells transfected with different mutant forms of KRas which show no
difference in growth on plastic but dramatic differences in anchorage-independent growth in a
clonogenic assay. The interaction between the pathways described in shown in Figure 26.
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Figure 23

Figure 23: Mek inhibition across a cell panel of NSCLC lines. No clear pattern was seen in
respect to IC50 of cell growth inhibition with AZ6244 in relationship to KRas activation except
when LKB1 loss of function was included. The two mut-KRas G12C lines with a concurrent
inactivating LKB1 mutation were the most sensitive to Mek inhibition (IC50 <10µM).
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Figure 24

Figure 24: Akt inhibition across a panel of NSCLC cell lines. No clear pattern was seen in
respect to IC50 of cell growth inhibition with regards to KRas activation. Those with
LKB1mutations fell into two distinct groups. One group sensitive to Akt inhibition (IC50<4µM)
which included two lines without concurrent mutant KRAS (the only two screened) and one
with a concurrent KRas G12C mutation. The second group of LKB1 mutants was resistant to
Akt inhibition (IC50>15µM) which all had a concurrent KRas mutation.
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Figure 25

Figure 25: TSC2 stabilization after treatment with KRas effecter pathway inhibition.
Measurement of TSC2 levels,degraded by Mek or Akt signaling and stabilized by LKB1 under
low energy, after treatment with either control (DMSO) or an AKT (MK2206) or MEK (AZ6244)
inhibitor. In LKB1 mutant lines sensitive to Akt inhibition treatment with 5µM MK2206 resulted
in an increased expression of TSC2 (black lines) over control (white lines) not seen in resistant
lines. Conversely, LKB1 mutant lines resistant to MK2206 showed stabilization of TSC2 with
Mek inhibition although this did not correlate with sensitivity to this agent. Stabilized TSC2
represses mTOR signaling and translation.
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Figure 26

Figure 26: LKB1 plays a role in sensitivity to inhibition of Akt or Mek pathways. In our
isogenic cell lines, the degree of growth inhibition by inhibitors of KRas effecter signaling was
related to the activating mutation of KRas, while in a panel of NSCLC cell lines, the presence
of inactivating mutations in LKB1 was found to influence response to these agents. KRas
G12C lines with concurrent LKB1 inactivation being the most sensitive. Additionally LKB1
mutation alone conferred sensitivity of Akt inhibition, while in a majority of cell lines a
concurrent KRas mutation conferred resistance. This effect was dependent on the ability of Akt
inhibition to restore TSC2 expression.
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4.3 siRNA treatment of isogenic lines with mutant KRas G12C
In chapter 3 it was determined that patients who harbored a mutant KRas G12C were
resistant to multiple types of targeted therapy. To find new methods to treat these cells a
genome wide siRNA screen was performed in the Mia Pa Ca-2 pancreatic cancer cell line
which harbors a KRas G12C allele and an isogenic line with this allele deleted dubbed M27.
The scheme for this screen is depicted in Figure 27.

4.3.1 Evaluation of direct KRas effecters
The validated KRas effecters described in Figure 3 were the first set of data analyzed.
siRNA directed towards these effecters had little effect of either the parental line or the M27
clone. Knockdown of BRaf, the Raf isoform primarily responsible for activating Mek/Erk
signaling38, inhibited growth in the M27 significantly more (p=0.03) than in the parental
although by only 16% (Figure 28). This finding may reflect recent findings elucidating a
complex interplay of dimerization between Raf isoforms that can be modified by the activation
of Ras isoforms in a melanoma model 114. This data may indicate that the different isoforms of
effecters or the effecters themselves are redundant, have feedback that negates the effect of
their inhibition, or that KRas G12C mutants are using an effecter pathway that has not fully
been characterized.
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Figure 27

Figure 27: siRNA screen of the Mia Pa Ca-2 cell line (KRas G12C) and the isogenic clone
with KRas deleted by homologous recombination. Each cell line was plated in 384 well
plates with a pool of siRNA’s targeting one gene already printed. Cells were allowed to growth
for 72 hours and then cell viability was read. Each siRNA treatment was expressed as a
fraction of the non-targeting control in the two cell lines. Finally these viabilities were compared
to compare the effects of each gene knockdown in the cell line with and without mut-KRas
G12C.
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Figure 28

Figure 28: Analysis of the canonical KRas effecter pathways. The six best characterized
KRas effecter pathways described in chapter 1 were analyzed. Cell viability was only reduced
below 90% of non-targeting control in the M27 mut-KRas null clone with the deletion of BRAF
while the parental Mia Pa Ca-2 cell line was not affected by this knockdown. Knockdown of
any other of these KRas effecters failed to reduce viability lower than 90% compared with nontargeting control.
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4.3.2 Determination and validation of siRNA hits
We selected “hits’ from the global siRNA screen based on their ability to selectively
inhibit growth in Mia Pa Ca-2 mutant KRas G12C cells but not the wild type- KRas M27 clone.
Once these “hits” were selected they validated using four second manufacturers siRNA’s in
both the Mia Pa Ca-2/M27 isogenic line and the HCT-116 colon cancer line with an activating
glycine to aspartate mutation in codon 13 and the HKH2 line the mutant KRAS allele deleted.
In these lines 7 of 10 of the hits from our screen validated by our criteria that 3 of 4 of the
individual siRNAs reflected the results seen in the initial screen. These results are shown in
Figure 29. siRNA screening in mutant KRAS null/positive has been reported by several other
groups and has yielded several “synthetic lethal” targets including COPB2, TBK1 and STK33
although the latter failed to reproduce in subsequent studies 96,112,113. We utilized our a similar
technique but shifted the focus of our analysis from siRNAs that simply inhibited the growth of
cells with mutant KRAS to a greater extent than those with wild-type KRAS regardless of the
viability, to focus specifically on targets which had no or minimal effect on the growth of our
wild type cells while having a significant effect on cells with mutant KRAS.
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Figure 29

Figure 29: siRNA’s which selectively reduced the viability of cells with mut-KRAS.
siRNA’s selected from the screen which reduced the viability of cell lines with a mut-KRAS
(Mia Pa Ca-2, top/ HCT-116 bottom) but had no effect of the viability of isogenic lines with this
mutant KRAS deleted (M27,top/HKH2, bottom). The four samples per target represent
individual siRNA’s to the same gene. Hits were considered validated if 3 out of 4 of these
siRNA’s produced a selective growth inhibition in the mut-KRAS line.
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4.4 Discussion
Using a set of isogenic colorectal cell lines expressing KRas WT, G12C or G12D from
the endogenous loci we have shown that the presence and type of activating mutation affect
the response of cells to inhibitors of the PI3K and Raf effecter pathways of KRas. In all
treatments that showed appreciable responses WT KRas cells were the most sensitive,
reinforcing previous studies showing that mut-KRAS acts as a marker of resistance to
inhibitors of the Raf-Mek and PI3K effecter pathways 80,109. I have shown previously that mutKRas 12C/V selectively activate the Raf-Mek inhibitor and RalGDS effecter pathways and
inhibited PI3K signaling, conversely, mut-KRas G12D activated the Mek and PI3K effecter
pathways but not the RalGDS pathway. Reflecting this, in colorectal cells engineered to
express mut- KRas G12C/V the strongest growth inhibition was seen with the Mek inhibitor
GSK1120212 while a weaker response was seen in KRas G12D expressing cells. In contrast,
treatment with the Akt inhibitor MK-2206 resulted in a stronger response in mut-KRas G12D
than in the mut-KRas G12C/V lines was observed reflecting the signaling pathways active in
these cells. Although notably different agents targeting the same enzyme gave different
results, indicating each particular agent evaluated may play a role in interpreting results.
Subsequent studies on a lung cell line with different forms of activated KRas expressed from a
plasmid showed that different KRAS mutants conferred different sensitivities to both cytotoxic
and molecularly targeted agents in cell growth assays 106. We next screened a Mek and Akt
inhibitor across a panel of 30 NSCLC cell lines to attempt to correlate response to these
inhibitors to differences in activating KRas mutations. However, to our surprise, no correlation
was observed. To address this, we integrated analysis of other genes that are frequently
mutated in NSCLC, many concurrently with KRAS, into our study. Loss of function mutations
in LKB1, a tumor suppressor protein responsible for inhibiting translation though the
stabilization of TSC2 under low energy conditions, is a common event in NSCLC115, and
frequently co-occurs with mut-KRAS116. Those pathways activated by LKB1 inactivation are
known to interact with KRas effecter pathways and cause changes in cellular signaling, cellular
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behavior, and response to targeted therapy. This reanalysis suggested that when these events
were evaluated together trends emerge with LKB1 inactivation in the absence of mut-KRAS
serving as a marker of response to the Akt inhibitor MK2006. Additionally one mut-LKB1/mutKRAS cell line showed a degree of sensitivity to MK2206 while others with this genotype
showed marked resistance. Both the Mek and Akt activation can induce the degradation of
TSC2 resulting in mTOR mediated translation. LKB1 serves as a regulator of this process,
activating in response to low intracellular energy levels and stabilizing TSC2 and inhibiting
translation, a high energy process, until intracellular energy levels can be restored. Measuring
protein levels in a panel of cells treated with MK2206 we found that those with LKB1 mutations
that displayed growth inhibition had increased TSC2 levels post exposure. This included both
a line with and a line without mut-KRAS mutation. All lines with mut- LKB1 and no response to
MK2206 displayed concurrent mut- KRAS and displayed no increase in TSC2 after MK2206
treatment. In contrast, this group of cells displayed increased TSC2 levels when treated with
AZ6244, although this did not correlate with response to this agent. Taken together this
indicates that the presence of LKB1 with a mut-KRAS may confound attempts to inhibit KRAS
though inhibition of the PI3K and Raf effecter pathways and the interactions of these pathways
may be variable perhaps reflecting a third unknown determinant or the order of acquisition of
these lesions.
Additionally, the Mia Pa Ca-2 line with and without the mut-KRAS 12C mutation was
evaluated against a genome wide siRNA screen. We found that none of the canonical effecter
pathways of KRAS had an important influence on the viability of these cells in the presence or
absence of mut-KRAS 12C. However we found a set of genes that when inhibited showed
increased growth inhibition in cells with mut-KRas 12C when compared to those cells with WT
KRas. These included components of the proteasome and clatherin complex described
previously96 and two PH domain containing proteins, uniquely identified by our screen, one of
which is a known component of the KRas nanocluster, necessary for KRas signaling. CNKSR1
(protein product is CNK1) is described in Chapter 5.
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Targeting KRas signaling through inhibition of the Ras nanocluster protein CNK1
5.1 Introduction
Many of the studies describing the activity of the Ras isoforms have been conducted
on the protein itself; however, it is known that Ras proteins do not exist on membranes with
only with their effecters, but rather as part of a “nanocluster” of scaffold and other accessory
proteins. These nanoclusters govern such functions as selective Ras isoform recruitment. An
example of this was seen in the G Protein signaling 14 (GPS14) receptor, found to selectively
activate HRas
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. When evaluated in in vitro assays GPS14 bound Ras-like proteins

promiscuously, however in cells there was HRas selective recruitment to the nanocluster,
facilitated by accessory proteins. Potential accessory proteins include gelectin family members
are known to associate selectively in different Ras nanoclusters, with gelectin1
with HRas, and gelectin 3 associating with KRas
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associating
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. Nucleolin has also been identified as a

selective KRas interacting protein, associating KRas with EGFR
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, although a different study

found over expressed nucleolin associated all active Ras isoforms with EGFR
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. The

discrepancies suggest a possible dynamic protein interaction. Our studies described below
have shown that the scaffold protein CNK1 can be classified as an essential component of the
KRas nanocluster, associating KRas with its effecter proteins. Furthermore we hypothesized
that inhibition of CNK1 by disrupting its proper localization represents a promising new
stragedy to inhibit KRas driven cancers.
5.2 CNKSR1 as a component of KRas signaling
CNK1 is a multi-domain protein that was first discovered through genetic studies that
identified Drosophila CNK (dCNK) as essential for the deranged eye phenotype induced by a
constitutively active Ras mutant 121. The N terminus of dCNK1 consists of a sterile alpha motif
(SAM) domain, a conserved region in CNK1 (CRIC) domain, a PSD-95/DLG-1/ZO-1 (PDZ)
domain and a C terminal proline-rich region containing a serine phosphorylation site and a
pleckstrin homology (PH) domain. dCNK1 has an extended C terminus not present in human
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CNK1 containing a Raf-inhibitory region (RIR) and a YELI site. Human CNKSR1 also has a
conserved region among chordates (CRAC) domain implicated in protein binding. In
Drosophila, growth factor receptor activation causes the YELI domain to bind dSrc
reconfiguring the RIR, thus allowing dRaf binding to dRas, while the N-terminus SAM domain
binds HYPEN (HYP) recruits Kinase Suppressor of Ras (dKSR).The resultant dKSR/dRaf
dimer allows dMek phosphorylation and initiates the Mapk signaling cascade122. Drosophila
has one Raf isoform, whereas mammals have three, (A-Raf B-Raf and C-Raf). B-Raf is
frequently found with a phosphorylation-mimicking mutation rendering it independently active,
whereas oncogenic KRas has been shown to selectively use the C-Raf isoform and
accordingly C-Raf is required for the initiation of lung cancer by K-Ras123. Studies with
mammalian CNK1 have shown a direct interaction between CNK1 and human HYP, B-Raf,
and C-Raf. Drosophila models also suggested that CNK1 may be involved in dRAL signaling
and subsequent studies showed direct binding between human CNK1 and RalGDS and the
GTPase RhoA. Finally these studies showed the CNK1 directly bound the PI3K effecter Akt in
human cell lines and was membrane localized. Figure 30 summarizes the KRas signaling
nanocluster found in Drosophila and humans. Together these studies suggest that CNKSR1
plays a role in multiple downstream pathways in KRas signal transduction. As described below
we performed an siRNA screen looking for gene that would selectively inhibit the growth of
cells with an oncogenic KRas while having no effect on an isogenic cell line with the mutated
KRAS allele silenced and identified human CNKSR1.
5.3 Results
5.3.1 Growth of NSCLC cell lines after CNKSR1 knockdown
We studied the ability of CNKSR1 knockdown to inhibit the growth of a panel of wild
type and mutant KRas NSCLC cell lines finding that in cells with an activating KRAS mutation,
siCNKSR1 had a growth inhibitory effect of 45% or greater (Figure 31). Additionally a growth
inhibitory effect was seen in the H1993 cell line with a wild type KRAS, a likely explanation is
that this wild type KRas cell has “mutant Ras-like properties” as previously been reported for
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NSCLC cell lines 124. Four other cell lines we tested with a wild type KRAS showed no
significant response to the knockdown of CNKSR1 suggesting they utilize of alternative
pathways to elicit cell growth and survival. The ability of siCNKSR1 to inhibit CNK1 expression
is represented in three NSCLC cell lines with wild type KRAS (two of which showed no CNK1
expression) and three NSCLC cell lines with mutant KRAS in Figure 32.
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Figure 30

Figure 30: CNK1 nanocluster signaling. The CNK1 protein was initially described in
Drosophlia as a scaffold for dRas signaling through the Mapk pathway by direct binding of
dRaf, dHYP and dKSR. The human CNK1 has also been implicated in the direct binding of Raf
but also the Ras effecters RhoA, RalGDS and PI3K. Figure 30 adapted from 125 .
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Figure 31

Figure 31: Viability of NSCLC cells after treatment with siCNKSR1. Cells were treated with
siCNKSR1 or non-targeting siRNA for 72 hours and cell proliferation was measured. A marked
decrease in viability was seen in all the mut-KRAS cells and one WT-KRAS line when
compared to cells treated with non-targeting siRNA. Other the WT-KRAS cells were
unaffected.
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Figure 32

Figure 32: Knockdown of CNK1 with siCNKSR1. Three NSCLC cell lines with wild type
KRAS and three lines with mutant KRAS (KRas G12C, G12V and G12A) were treated with
siCNKSR1 or non-targeting siRNA for 48 hours and protein expression was measured. Two of
the three wild type cell lines displayed no CNK1 expression while one line had CNK1
expression but showed no viability decrease (Figure 31) despite no CNK1 being detectable
after siCNKSR1 treatement. In mutant KRAS lines CNK1 was detectable in all lines tested and
siCNKSR1 resulted in undetectable CNK1 in all lines tested. Actin served as a loading control
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5.3.2 Effect of oncogenic KRAS and CNKSR1 deletion on spheroid formation
Initial studies characterizing HCT-116 and the HKH2 line with a deleted mut-KRAS
allele found that the HKH2 clone grew at half the rate of the parental line in adherent 2D
conditions, similar to what we observed with CNKSR1 knockdown in Figure 29. The initial
studies additionally characterizing the HKH2 line showed more dramatic effects in 3-D assays
such as colony formation or xenograft formation126. We explored this using a spheroid
formation assay we investigated the ability of HCT-116 and HKH2 to form spheroids under
non-adherent conditions. While HCT-116 formed large (>300 µM) spheroids, HKH2 cells
aggregated together but failed to grow (Figure 33). We next determined if this phenotype
could be reproduced by knockdown of CNKSR1. We treated HCT-116 with a non-targeting
siRNA and an siKRAS to serve as a negative and positive control, respectively. HCT-116
treated with siSCR grew similar to untreated cells while siKRAS inhibited spheroid formation in
a similar fashion to HKH2 (Figure 34). HCT-116 cells treated with siCNKSR1 formed
aggegerates similar to those created by HKH2 and HCT-116 cells.

5.3.3 CNKSR1 deletion induces anoikis in a KRAS dependent manner.
Activated KRas has been shown to inhibit anoikis, apoptosis caused by detachment
from a matrix, in cancer cells127. To determine if CNKSR1 deletion restores anoikis, we treated
HCT-116 and HKH2 cells with non-targeting siRNA, siCNKSR1 or siKRAS. We found that
siRNA to CNKSR1 and siKRAS selectively induces anoikis in HCT-116 but not HKH2 cells as
shown in Figure 35.
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Figure 33

Figure 33: Spheroid formation in the presence or absence of mut-KRas. 20,000 HCT-116
or HKH2 cells were put into a hanging drop in a 3-D meshed plate. HCT-116 with a mut-KRAS
allele formed spheroids greater the 300µM in size. In contrast, the isogenic clone of HCT-116,
HKH2, with the mut-KRAS allele deleted formed only small aggregates which failed to
proliferate.
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Figure 34

Figure 34: Spheroid formation in in HCT-116 cells after treatment with siCNKSR1 or
siKRAS. HCT-116 cells were treated with non-targeting siRNA or siCNKSR1 48 hours before
plating in hanging drops. The HCT-116 cells treated with non-targeting siRNA formed
spheroids greater than 300 µM similar to untreated HCT-116 cells (Figure 32). HCT-116 cells
treated with siCNKSR1 or siKRAS displayed a phenotype similar to HKH2 cells forming small
aggregates which fail to proliferate (Figure 32).
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Figure 35

Figure 35: Anoikis in HCT-116 and HKH2 cells. HCT-116 and the HKH2 variant cells were
treated with non-targeting siRNA (SCR5), siCNKSR1 or siKRAS. These cells were then put in
non-adherent, single cell conditions for 24 hours and apoptosis was measured. It was found
that siCNKSR1 or siKRAS significantly increased anoikis in HCT-116 cells while having
minimal effect on HKH2 cells, indicating that signaling by both mut-KRas G13D and CNK1
were inhibiting anoikis in HCT-116 cells.
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5.3.4 Analysis of signaling responsible for growth inhibition
To determine the molecular mechanism by which the knockdown of CNKSR1
mimicked the absence of oncogenic KRAS we subjected both the mutant KRas HCT-116 and
wild type KRas HKH2 cell lines, and a panel of wild type and mutant KRas NSCLC cell lines to
RPPA analysis after treatment with non-targeting control or siCNKSR1. To first determine the
optimal time to measure the effects of CNKSR1 knockdown, siSCR (non-targeting siRNA) or
siCNKSR1 was added to the cells and levels of the CNK1 protein were measured after
different times (Figure 36). After treatment with siCNKSR1, CNK1 protein began to decline at
24 hours and was undetectable at 48 hours and remained inhibited at 72 hours. We next
observed the proteins showing largest charge in HCT-116 when treated with siCNKSR1 and
compared those to levels in HCT-116 and HKH2, the isogenic line for mut-KRAS in an attempt
to characterize the mechanisms responsible the observations in our siRNA screening results
(Figure 37). CNKSR1 knockdown caused a large decrease in both Cyclin B and
phosphorylated Rb in both the isogenic KRas cells and the cell line panel. Cdk1, which
couples with Cyclin B to make the mitosis promoting factor necessary for cell cycle
progression into mitosis, was also down regulated in both conditions. This is notable as a
previous study on these isogenic lines with an shRNA library found that HCT-116 was more
sensitive to deletion of several components of mitotic signaling including Plk1 than its isogenic
partner 96. Additionally, Rb phosphorylation at the site responsible for its inactivation and
resulting in cell cycle progression, was significantly inhibited in a manner similar to that seen in
MEFs created with an absence of Ras signaling128. To test whether this effect was specific to
the HCT-116 cell line or broadly applicable, we additionally performed RPPA on a collection of
pancreatic, colon and lung cancer cell lines and found that all lines tested showed knockdown
of Cyclin B and Cdk1 (p<0.01) additionally the phosphorylation of Rb1 at the serine 807 site was
significantly downregulated (p<0.05) (Figure 38). Additionally Fak (p<0.01) and Chk1 (p<0.05)
were significantly down-regulated in this cell line panel after siCNKSR1 knockdown (data not
shown), also observed with the deletion of the mut-KRAS allele. These changes occurred after
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CNKSR1 deletion regardless of the type of amino acid substitution responsible for activating
KRas indicating a universal mechanism for inhibition of KRas signaling. A significant
difference between siCNKSR1 and the deletion of mut-KRAS allele was that while
phosphorylated YB-1 was up regulated after siCNKSR1 treatment (p<0.05) in this panel,
deletion of the mut-KRAS allele resulted conversely in down regulation of this phosphorylation
site (Figure 37), indicating siCNKSR1 is not an exact phenocopy of the deletion of a mutKRAS allele.

84

Figure 36

Figure 36: Time course for knockdown of CNK1 with siCNKSR1. Non-targeting siRNA or
siCNKSR1 was applied to cells at indicated time points before lysing and probing for CNK1
with a specific antibody. Actin served as a loading control.
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Figure 37

Figure 37: Comparison of HCT-116 treated with siCNKSR1 to a mut-KRAS null clone by
RPPA. The change (in arbitrary units) in the ten most down regulated proteins by siCNKSR1
when compared with non-targeting siRNA (blue) compared to the change between HCT-116
and the HKH2 clone (red). Several cell cycle proteins including Cyclin B, phosphorylated Rb,
Cdk1 and Chk1 were down regulated in both conditions.
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Figure 38

Figure 38: Cell cycle proteins significantly changed in a panel of cells after treatment
with a non-targeting control and siCNKSR1 as determined by RPPA. Cyclin B and Cdk1
form the mitosis promoting factor and were both significantly down-regulated after siCNKSR1
treatment. Phosphorylated Rb was also down-regulated after siCNKSR1 treatment. Notably
this was the same phenotype seen in Rasless MEFs128.
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5.3.5 Cell Cycle analysis after CNKSR1 knockdown
A decrease of Cyclin B and Cdk1 indicates the ability of cells to form the Mitosis
Promoting Factor and a failure to progress through the cell cycle while the phosphorylation of
Rb is essential for progression past the G1 stage. To determine whether the changes in cell
cycle proteins seen with the knockdown of CNKSR1 had functional consequences we
subjected our cells to cell cycle analysis. We found that HKH2 cells without mutant KRas
showed an increase of cells in the G1 phase of the cell cycle compared to HCT-116 cells with
mutant KRas. Thus, knockdown of CNKSR1 has a modest effect in HKH2 cells, but strongly
induces G1 arrest in HCT-116 cells (Figure 39). We next compared the cell cycle of a mutKRas G12V cell line which showed decreased viability with to CNKSR1 (H441) knockdown to
a cell line with wild type KRAS which expresses CNK1(Figure 32) but showed no response to
CNKSR1 knockdown (HCC95). As expected H441 accumulated in the G1 phase of the cell
cycle while the HCC95 resistant line showed little effect of CNKSR1 knockdown (Figure 40).
These results strongly suggest that the decreased proliferation seen in our panel of NSCLC
cell lines is a result of the cells accumulating in G1. Additionally since the HCT-116 line has a
mut-KRas G12D and H441 an activated KRas G12V the findings suggest that the G1 arrest is
independent of the amino acid substitution responsible for KRas activation.
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Figure 39

Figure 39: Cell cycle analysis of HCT-116 and HKH2 cells treated with siKRAS or
siCNKSR1. HCT-116 cells lacking the mut-KRAS allele (HKH2) show a higher proportion of
cells in the G1 phase of the cell cycle which is unchanged by the addition of siKRAS or
siCNKSR1. HCT-116 (mut-KRas G13D) cells show a greater distribution of cells through the
cell cycle than HKH2 but show an increase in cells in the G1 phase with both siKRAS and
siCNKSR1.
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Figure 40

Figure 40: Cell cycle analysis of NSCLC cells. HCC95 (WT KRAS) and H441 (mut-KRAS)
showed a similar distribution through the cell cycle. Treatment of HCC95, which showed no
viability change with siCNKSR1, with siKRAS or siCNKSR1 showed no effect on the cell cycle
distribution of these cells. H441, which showed decreased viability with siCNKSR1 treatment,
showed an increase in the G1 phase of the cell cycle after treatment with both siKRAS and
siCNKSR1.
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5.3.6 CNK1 localization with mutant KRas
In the Drosophila studies dCNK and dRas in drospohlia were found co-localized in the
cellular membrane

121

. To address the question whether in mammalian cells there is a

membrane association of fluorescent protein tagged CNK1 and KRas, we used confocal
microscopy and a technique known as Fluorescence Lifetime Imaging Microscopy. The basis
of FLIM is that upon excitation, if the protein GFP tag is within the critical distance of 10 nm of
another protein with a red fluorescent protein RFP tag, FRET (Förster resonance energy
transfer) occurs from the donor (GFP) to the acceptor (RFP). This results in a reduction of the
emission lifetime of the donor GFP which is measurable and indicates a direct interaction
within 10 nM. The use of FLIM to detect FRET has the advantage that only the GFP donor
fluorescence needs to be measured. HEK293 cells were transfected with either a WT or a
mutant KRAS 12D tagged with red fluorescent protein (RFP) and CNK1 tagged with green
fluorescent protein (GFP) allowed to grow for 48 hours and fixed on slides.
In the cells transfected with wild type KRAS and CNK1, CNK1 was largely cytoplasmic and the
WT KRAS was localized to the membrane, there was a small level of co-localization at the
membrane, however, the lifetime of CNK1 GFP after excitation was similar to that of our cells
transfected with only CNK1 GFP, indicating that there was colocalization (less than 500 nm)
but no direct interaction (ie more than 10 nM) with the WT KRas RFP. HEK293 cells
transfected with mut-KRAS 12D and CNKSR showed a markedly transformed phenotype with
elongated cells and branching morphology. In these cells these two proteins were found
colocalized at the cellular membrane in distinctive clusters (Figure 41). Additionally, the
lifetime of the GFP was reduced suggesting that they were in close proximity, with less than 10
nM separating them (Figure 42).
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Figure 41

Figure 41: Confocal of CNK1 and KRas. CNK1 was tagged with GFP and either WT KRAS
or mut-KRAS G12D were tagged with RFP. These fusion proteins were then co-transfected in
HEK293 cells and serum starved overnight. In cells transfected with CNK1 GFP and WT
KRAS GFP CNK1 protein was primarily cytoplasmic and KRas was mostly localized to the
membrane, which no or little co-localization occurring. The cells transfected with mut-KRAS
displayed a dramatic change in morphology with a fiberous appearance. These cells showed
co-localization of CNK1 protein and mut-KRas at the membrane and at the tips of fibrous
extensions.
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Figure 42

Figure 42: FLIM analysis of CNK1and KRas. Fluorescence Lifetime Imaging Micorscopy
was used to analyze interaction between CNK1 and either WT KRas or Mut-KRas G12D. Cells
transfected with CNK1-GFP alone served as a control. When co-transfection of CNK1 and WT
KRas was performed, the lifetime of GFP after excitation was similar to what was seen in our
CNK1-GFP alone sample. In contrast, a dramatic decrease was seen in this lifetime with the
co-transfection of CNK1 and mut-KRas G12D indicating that electrons were being transferred
to RFP, meaning the two fusion proteins are within 10nM of each other.
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5.4 Rationale for CNK1 as a target for cancer therapy
siRNA to CNKSR1 inhibits growth in all the oncogenic KRas cancers we have tested,
regardless of the activating mutations or tissue origin. However since CNK1 is not an active
(ATP utilizing) enzyme it is unclear how to approach CNK1 as a target for cancer therapy. The
PH domain of CNK1 binds to the same negatively charged phospholipids as the polybasic
domain in the KRas hypervarible region 129 but with higher affinity to membrane
phosphatidylinostol-2- and 3-phosphates (PIP2, PIP3) and is critical for the proper localization
of CNK1. As small molecules which bind to the PH domains of the Akt and PDK1 kinases have
previously been developed130, we postulated that it should be possible to use this paradigm as
a way to inhibit CNK1 by inhibiting its proper localization with mutant KRas.
5.4.1 Viability of NSCLC cells with treated of a dominant negative PH domain
To test the hypothesis that binding molecules to the PH domain would be an effective
method to inhibit the activity of CNK1, we expressed only the PH domain of CNK1 without any
other portions of the protein present. This PH domain fragment retained the ability to bind PIP2
and PIP3 with KD’s of 144 and 146 nM respectively. This PH domain occupied the PIP2/3 lipids
on the membrane but had none of the other domains important for signaling. As such it has
characteristics of a dominant negative and blocked the growth of mutant KRas cells. We
transfected the NSCLC line H1373 whose growth is inhibited by siCNKSR1 with either the PH
domain of CNK1 or a vector controland found transfection efficacy to be ~99% as measured
by the presence or absence of GFP expressed independly by the vector or fused to our GFP
construct. The viability of these cells was then measured after 72 hours. We found a significant
(p<0.05) 48% reduction in viability similar to the 49% reduction in viability seen by siCNKSR1
in Figure 43.
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Figure 43

Figure 43: Expression of a dominant negative PH domain in NSCLC cells. A GFP only
expressing vector control and the CNK1 PH domain- GFP fusion lacking any other protein
domains was inserted in H1373 NSCLC cells, known to be sensitive to CNKSR1 knockdown.
Transfection efficiency was measured by the presence of GFP and found to be ~99%.The
empty vector had no effect on the proliferation of the cells, but the cells transfected with the
PH domain showed a significant decrease in viability (p<0.05) after 72 hours.
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5.4.2 Identification of agents inhibiting CNK1
A homology model for the PH domain was developed in collaboration with the Dr.
Zhang in the Computer Modeling Core at the Center for Targeted Therapy at MD Anderson.
The first set of analogs was screened for the selective inhibition of growth in HCT-116 (mutant
KRAS) and HKH2 (wild type KRAS) cells for 72 hours. While compound 1 showed nonselective killing of both cell lines, compound 4 and 7 in the series showed selective inhibition of
the growth of the mut-KRAS cells and less activity against WT-KRAS cells (Figure 43). The
compounds that showed activity were then screened against a set of lung cancer lines with
known sensitivities to siCNKSR1, four with WT-KRAS that are insensitive to CNKSR1
knockdown and four with mut-KRAS that showed sensitivity to siCNSKR1 knockdown. In these
lines compound1 showed dramatic growth inhibition against all lines tested. In contrast
compound 4 and compound 7 showed growth inhibition in only the four lines with mut-KRAS
that had been found sensitive to siCNKSR1 (Figure 44). Finally, all compounds were tested
for direct binding to the recombinant CNK1 PH domain and the Akt PH domain using Surface
Plasmon Resonance (SPR) spectroscopy to determine if the binding was specific. Compound
1 and 4 had undetectable binding. Compound 7 however bound with a KD of 3.2 µM to the
CNK1 PH domain and 17 µM to the Akt PH domain. Finally, several analogs of compound 7
were created. Two of these 7.3 and 7.5 showed improved affinity to the CNK1 PH domain
while still retaining selectivity (Table 2).
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Figure 44

Figure 44: Screening of agents targeting the CNK1 PH domain against isogenic lines.
Compounds identified in an in-silico screen were tested at 25 and 50µM concentrations in
HCT-116 and the isogenic HKH2 cell line. In Figure 29 we showed that knockdown of
CNKSR1 inhibited the viability of HCT-116 cells while having minimal effects on the HKH2
clone, thus we selected agents which showed the greatest effects against HCT-116 while
having minimal effects against HKH2. Compounds 4 and 7 showed the greatest selective
effect. Additionally Compound 1 showed potent cell killing against both lines.
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Figure 45

Figure 45: Screening of lead compound hits in a panel of NSCLC cell lines. As
compounds 1,4, and 7 showed activity against our isogenic lines, we evaluated the activity of
these agents in a panel of NSCLC cancer cells with known KRAS status and sensitivity to
CNKSR1 inhibition and determined the IC50 values. As we had seen in our initial screen,
Compound 1 inhibited the viability of all the cell lines tested. Compound 4 decreased viability
in some but not all of the mut-KRAS cell lines which also showed sensitivity to CNKSR1
knockdown. Compound 7 didn’t effect proliferation in any of the WT KRAS lines but inhibited
proliferation in the mut-KRAS lines tested.
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Table 2

Table 2. SPR to determine binding of lead compounds and analogs to the PH domain of
CNK1 and Akt. SPR was used to determine binding of the lead compounds to the
recombinant PH domains of Akt or CNK1. N.B. indicates no detectable binding. Compound 1
or 4 failed to give a binding value indicating no or weak binding. Compound 7 gave a KD of 3.2
µM and 17µM to the recombinant CNK1 and Akt PH domain respectively. Additionally a series
of analogs was made to compound 7 which showed increased binding to the CNK1 PH
domain while still retaining selectivity towards the Akt PH domain.
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5.5 Discussion
We identified CNKSR1 as a gene that selectively inhibited the growth of cells with a
mutant-KRAS. Here we screened a panel a NSCLC lines against a putative small molecule
inhibitor of the PH domain of CNK1 and found that the growth of all the mut-KRAS was
inhibited while a majority of the WT-KRAS did not show any inhibition of growth. Notably, one
WT-KRAS line did show a response to inhibition indicating that there may be a sub-population
of wild type KRas lines with a KRas-like phenotype that may be responsive to CNKSR1
inhibition. Using RPPA analysis we found that deletion of CNKSR1 mimicked deletion of the
mut-KRAS allele in the down regulation of phosphorylated Rb and the components of the
mitosis promoting factor, Cyclin B and Cdk1. This finding was validated across a large panel of
cell lines, with every line treated showing a decrease in these proteins. Our isogenic lines and
NSCLC lines with and without mut-KRAS were then used to show that treatment with
siCNKSR1 induced an increase in the G1 phase of the cell cycle. This is intriguing for several
reasons, the first being that mice engineered to express activated NRas or KRas in the colon
showed that while NRas increased resistance to apoptosis, KRas activation caused
uncontrolled proliferation. Similarly, MEFs engineered to be devoid of any Ras activity
mimicked the phenotype seen in our CNKSR1 knockout, expressing Cdk4 and Cyclin D, but
finding no activity at the Rb ser807 which is known to phosphorylate and not expressing Cdk1
or Cyclin B128. Finally, using the same set of isogenic lines in which we did many of our
studies, a shRNA screen found that the Mut-KRAS cells were sensitive to inhibition of mitosis
when compared to cells with just the wild type allele 96. To our surprise, despite these dramatic
changes in cell cycle, no consistent change was seen by RPPA in the canonical Mapk or Akt
effecter pathways (data not shown). Studies have found that C-Raf promotes mitosis in a Mek
and ATP-dependent fashion131 and similarly binds to Rb132 and that C-Raf is necessary for
KRas driven tumor development independently of Mek signaling 66,133. Given the well
characterized role of CNK1 and Raf in Drosophlia signaling 121, it is tempting to speculate that
increased Mek independent C-Raf signaling may be the mechanism responsible for CNK1
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driving KRas mediated growth. Supporting this idea, our studies showed that while WT-Ras
and CNK1 had little or no co-localization, mut-KRas and CNK1 had a highly focal localization
in clusters and FLIM microscopy revealed that these two proteins were with 10 nm of each
other at the cellular membrane indicating the presence of an analogous association of proteins
as is seen in Drosophila. Drosophila has one Raf isoform while mammals have three, and the
association of CNKSR1 may be specific for C-Raf and act in a Mek independent fashion. An
additional hypothesis is that a less characterized KRas effecter may drive the effects of CNK1
deletion. The observation that C-Raf knockdown failed to have a selective effect in the
isogenic lines strengthens this idea. A proposed model of how CNK1 drives KRas driven cell
cycle progression is shown in Figure 46. The knockout of CNKSR1 had similar effects to
deletion of the mut-KRAS allele or siKRAS in a 3-D spheroid formation assay and an anoikis
assay, indicating that knockout of CNKSR1 had similar consequences on phenotype both in 2D and 3-D assays, thus, validating what we saw in our siRNA screen and validating its
importance in KRas driven tumors Finally, we showed that either a dominant negative PH
domain or small molecules development has begun on to inhibit the PH domain had similar
consequences to knockout of CNKSR1 with siRNA.
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Figure 46

Figure 46: CNK1 and KRas cooperate to drive progression through the cell cycle. CNK1
and KRas interact in the nanocluster, brought together by membrane lipids, to facilitate KRas
signaling through effecters and resulting in cell cycle progression. This interaction is promoted
in cells with mutant KRas resulting in a sustained interaction between the two proteins. We
have identified a lead compound with binds to the PH domain of compound 7 inhibits its
interaction with membrane lipids and thus disrupts the nanocluster.
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Chapter 6 Summary and future directions
6.1 Future directions regarding differing KRas effecter utilization
In chapter 3 it was discovered that the the identity of the amino acid activating KRas at
codon 12 influences which effecter pathways the KRas enzyme will utilize to promote
tumorigensis. Two major implications immediately arise from this discovery. The first relates to
scientific studies which have previously and continue to define the properties of KRas.
Historically, studies performed with different amino acid substitutions utilized to activate KRas
have been cross-referenced. My new results indicate that these experiments may be
fundamentally different as the KRas enzyme will behave differently depending on how it is
activated, thus a study performed with a mut-KRas G12D model must be compared to another
KRas G12D model and cannot be directly compared with a study which has used a G12V
substitution to activate KRas. Additionally, as we have shown that KRas G12D behaves
differently than a KRas G12C, the widespread use of a mouse model harboring a conditionally
activated KRas G12D to study lung cancer79, as opposed to a G12C activating substation
predominantly found in this disease, may warrant reevaluation. Thus the mouse model with a
KRas G12C activating mutation which has been described in the literature92 should become
the defaut to characterize NSCLC.
The second is the analysis of both traditional and targeted therapies in tumors in
relationship to KRAS status. Rather than evaluate KRAS mutation as a homogenous group, it
is more precise to look at individual KRAS activating mutations particularilty in, but not limited
to, inhibitors of KRas effecter signaling. These studies will likely be limited by low patient
numbers as we encountered in the BATTLE trial and ultimately may require large scale studies
as was performed in the RASCAL87 and RASCAL II88 trials or retrospective combined analysis
of several trials. Finally, recent years have seen numerous attempts to find genes patterns
(‘signatures’) which define cancers driven by mut-KRAS or display “KRAS-like” properties124.
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Attempts to build these signatures may be hindered by the grouping of the KRas enzyme
activated by different amino acids. In light of this, tailoring signatures to individual KRas
mutations and comparing these to wild type KRas models may be more informative and allow
use of these signatures for classification, treatment decisions, and the identification of future
therapeutic targets
6.2 Future directions in targeting KRas effecters
Chapter 3 suggested that the amino acid substation by which KRAS is activated in
cells would play a role in the response of these cells to the inhibition of different KRas effecter
proteins, an idea validated in chapter 4. However while different levels of response were seen
to inhibitors of the Mapk or PI3K pathways, none of these agents showed reponses greater
than 80% growth inhibition even at concentrations well above those required to inhbit the
target enzymes. Chapter 3 indicated responses are likely mitigated by feedback pathways
derepressed with effecter inhibition and growth factor signaling reactivation and this is a topic
which warrents further exploration.This has been addressed in experimental models by the
similtaneous inhibition of both the Raf and PI3K KRas effecters, thus eliminating potential
redundancy or feedback between these pathways in KRas signaling. This stragedy is now in
clinical trials for mutant KRas tumors in many different cancer types. Despite some promising
responses, early data is indicating that the combination may also have unacceptable
toxicity134. However, as multiple agents are in clinical trials targeting different nodes in these
pathways and adminsitered in different scheduling regimines, an acceptable combination may
be found.
Should agents be found which show promise either alone or in combination in KRas
mutant tumors, chapter 4 highlighted the importance of looking at multiple known oncogenic
lesions when determining treatment efficacy in contrast to looking at KRAS mutation as a
single marker. This was explored with concurrent KRAS activating and LKB1 inactivating
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mutations, occurring frequently in lung cancers in chapter 4 and similar observations have
been made with KRAS activating and PIK3CA activating mutations which occur frequently in
colorectal cancer135. While a majority of studies have focused on the presence of two
mutations as a marker of resistance to an inhibitior of one on these individual targets, it is
notable that at least one study has found the co-occurance of KRAS and LKB1 inactivating
lesions in lung cancer to be a predictor of single agent activity of a Mapk inhibitor136. Our data
in chapter 4 supported this, with G12C and LKB1 mutant tumors showing increased sensitivity
to AZ6244. Thus by not looking at the co-occurance of two oncogenic lesions as independent
events but understanding how these lesions interact in cellular signaling pathways it may be
possible to predict a single agent which may be utilized for therapeutic benefit, negating
increased toxicity from the combination of multiple agents.
6.3 Future directions for CNK1
In chapter 5, the deletion of CNKSR1 was shown to selectively inhibit the growth of
isogenic cells with an activated KRas allele and inhbit the growth of cells in a panel which
harbored any form of activated KRas. This is likely due to a physical association between
CNK1 and KRas in the “nanocluster” of proteins which occurs at the cell membrane and
faciliatates KRas effecter signal transduction. Additionally, CNK1 harbors a PH domain which
localizes this protein with KRas at the membrane and serves as a drugabble point to inhibit
this interaction. We found KRas utilizes CNK1 to drive cells cycle progression but the precise
pathway by which this occurs in human cells needs to be eluciadated. Previous studies in both
human and drosophlia cells suggest that a Mapk independant CRaf/RhoA pathway is a likely
candidate. This would contrast the the drospholia CNK which utilizes Mapk and why these
differences occur is a point of interest likely relating to the precence of a single Raf isoform in
Drosophlia and the evolution of three distinct Raf isoforms in humans.
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As a therapeutic target, it is notable that CNK1 deletion in our in vitro settings results in
cell cycle arrest but shows no indication of induction of apoptosis. The deletion has never been
performed in an in-vivo setting where factors such as tumor stress occur and may yield
different results and these experiements must be performed. If cell cycle arrest is the only
consequence of CNKSR1 deletion, addition agents may need to been combined with CNK1
inhibiitors to achieve not only an arrest of tumor growth but to achieve the induction of
apoptosis currently thought necessary for tumor regression. If these combinations prove
effective, the increased toxicity that may result from these combinations must be considered
as with Mek and Akt inhibitors but the unique association between CNK1 and mutant KRas
encourages the idea a favorable profile will exist. Finally, while the class of agents we have
developed to inhibit CNK1 localization are promising in our in-vitro experiements, continued
study will be necessary to determine if inhibition of localization is equivalent to deletion of
protein expression. Finally, if these agents continue to show promise in an in-vitro setting,
experiments in animals will be necessary for further development. This will require these
agents show acceptable pharmacokinetic and pharmacodynamics properities or modifications
may be necessary. If these hurdles are overcome, the inhibition of CNK1localization will
emerge as an exciting new therapeutic option for patients with tumors harboring the KRAS
oncogene.
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